<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="alz13879" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Dement</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Dement</journal-id><journal-id journal-id-type="pmc-domain-id">4549</journal-id><journal-id journal-id-type="pmc-domain">alzdem</journal-id><journal-id journal-id-type="publisher-id">ALZ</journal-id><journal-title-group><journal-title>Alzheimer's &amp; Dementia</journal-title></journal-title-group><issn pub-type="ppub">1552-5260</issn><issn pub-type="epub">1552-5279</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11497668</article-id><article-id pub-id-type="pmcid-ver">PMC11497668.1</article-id><article-id pub-id-type="pmcaid">11497668</article-id><article-id pub-id-type="pmcaiid">11497668</article-id><article-id pub-id-type="pmid">39132759</article-id><article-id pub-id-type="doi">10.1002/alz.13879</article-id><article-id pub-id-type="publisher-id">ALZ13879</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Leptin bioavailability and markers of brain atrophy and vascular injury in the middle age</article-title><alt-title alt-title-type="left-running-head">CHARISIS <sc>et al.</sc></alt-title></title-group><contrib-group><contrib id="alz13879-cr-0001" contrib-type="author"><name name-style="western"><surname>Charisis</surname><given-names initials="S">Sokratis</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6578-393X</contrib-id><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0002" contrib-type="author"><name name-style="western"><surname>Short</surname><given-names initials="MI">Meghan I.</given-names></name><xref rid="alz13879-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="alz13879-cr-0003" contrib-type="author"><name name-style="western"><surname>Bernal</surname><given-names initials="R">Rebecca</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0004" contrib-type="author"><name name-style="western"><surname>Kautz</surname><given-names initials="TF">Tiffany F.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0005" contrib-type="author"><name name-style="western"><surname>Treviño</surname><given-names initials="HA">Hector A.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0006" contrib-type="author"><name name-style="western"><surname>Mathews</surname><given-names initials="J">Julia</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0007" contrib-type="author"><name name-style="western"><surname>Dediós</surname><given-names initials="AGV">Angel Gabriel Velarde</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0008" contrib-type="author"><name name-style="western"><surname>Muhammad</surname><given-names initials="JAS">Jazmyn A. S.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0009" contrib-type="author"><name name-style="western"><surname>Luckey</surname><given-names initials="AM">Alison M.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0010" contrib-type="author"><name name-style="western"><surname>Aslam</surname><given-names initials="A">Asra</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0011" contrib-type="author"><name name-style="western"><surname>Himali</surname><given-names initials="JJ">Jayandra J.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz13879-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz13879-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz13879-cr-0012" contrib-type="author"><name name-style="western"><surname>Shipp</surname><given-names initials="EL">Eric L.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0013" contrib-type="author"><name name-style="western"><surname>Habes</surname><given-names initials="M">Mohamad</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="alz13879-cr-0014" contrib-type="author"><name name-style="western"><surname>Beiser</surname><given-names initials="AS">Alexa S.</given-names></name><xref rid="alz13879-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz13879-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz13879-cr-0015" contrib-type="author"><name name-style="western"><surname>DeCarli</surname><given-names initials="C">Charles</given-names></name><xref rid="alz13879-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz13879-cr-0016" contrib-type="author"><name name-style="western"><surname>Scarmeas</surname><given-names initials="N">Nikolaos</given-names></name><xref rid="alz13879-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="alz13879-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="alz13879-cr-0017" contrib-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names initials="VS">Vasan S.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz13879-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="alz13879-cr-0018" contrib-type="author"><name name-style="western"><surname>Seshadri</surname><given-names initials="S">Sudha</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz13879-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz13879-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="alz13879-cr-0019" contrib-type="author"><name name-style="western"><surname>Maillard</surname><given-names initials="P">Pauline</given-names></name><xref rid="alz13879-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="alz13879-cr-0020" contrib-type="author" corresp="yes"><name name-style="western"><surname>Satizabal</surname><given-names initials="CL">Claudia L.</given-names></name><xref rid="alz13879-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="alz13879-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="alz13879-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>satizabal@uthscsa.edu</email></address></contrib></contrib-group><aff id="alz13879-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases</named-content>
<institution>UT Health San Antonio</institution>
<city>San Antonio</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="alz13879-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Institute for Clinical Research and Health Policy Studies</named-content>
<institution>Tufts Medical Center</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz13879-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>The Framingham Heart Study</institution>
<city>Framingham</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz13879-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Biostatistics</named-content>
<institution>Boston University School of Public Health</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="alz13879-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University of California, Davis</institution>
<city>Sacramento</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="alz13879-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">1st Department of Neurology</named-content>
<institution>National and Kapodistrian University of Athens</institution>
<city>Athens</city>
<country country="GR">Greece</country>
</aff><aff id="alz13879-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Taub Institute for Research in Alzheimer's Disease and the Aging Brain</named-content>
<named-content content-type="organisation-division">the Gertrude H. Sergievsky Center</named-content>
<institution>Columbia University</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Claudia L. Satizabal, Glenn Biggs Institute for Alzheimer's &amp; Neurodegenerative Diseases, UT Health San Antonio, 7703 Floyd Curl Drive, MSC 8070, San Antonio, TX 78229, USA.<break/> Email: <email>satizabal@uthscsa.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>20</volume><issue seq="40">9</issue><issue-id pub-id-type="pmc-issue-id">473307</issue-id><issue-id pub-id-type="doi">10.1002/alz.v20.9</issue-id><fpage>5849</fpage><lpage>5860</lpage><history><date date-type="rev-recd"><day>01</day><month>3</month><year>2024</year></date><date date-type="received"><day>14</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>24</day><month>10</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-24 11:25:16.703"><day>24</day><month>10</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2024 The Author(s). <italic toggle="yes">Alzheimer's &amp; Dementia</italic> published by Wiley Periodicals LLC on behalf of Alzheimer's Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ALZ-20-5849.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:ALZ-20-5849.pdf"/><abstract><title>Abstract</title><sec id="alz13879-sec-0010"><title>INTRODUCTION</title><p>We investigated the associations of leptin markers with cognitive function and magnetic resonance imaging (MRI) measures of brain atrophy and vascular injury in healthy middle‐aged adults.</p></sec><sec id="alz13879-sec-0020"><title>METHODS</title><p>We included 2262 cognitively healthy participants from the Framingham Heart Study with neuropsychological evaluation; of these, 2028 also had available brain MRI. Concentrations of leptin, soluble leptin receptor (sOB‐R), and their ratio (free leptin index [FLI]), indicating leptin bioavailability, were measured using enzyme‐linked immunosorbent assays. Cognitive and MRI measures were derived using standardized protocols.</p></sec><sec id="alz13879-sec-0030"><title>RESULTS</title><p>Higher sOB‐R was associated with lower fractional anisotropy (FA, <italic toggle="yes">β</italic> = −0.114 ± 0.02, <italic toggle="yes">p</italic> &lt; 0.001), and higher free water (FW, <italic toggle="yes">β</italic> = 0.091 ± 0.022, <italic toggle="yes">p</italic> &lt; 0.001) and peak‐width skeletonized mean diffusivity (PSMD, <italic toggle="yes">β</italic> = 0.078 ± 0.021, <italic toggle="yes">p</italic> &lt; 0.001). Correspondingly, higher FLI was associated with higher FA (<italic toggle="yes">β</italic> = 0.115 ± 0.027, <italic toggle="yes">p</italic> &lt; 0.001) and lower FW (<italic toggle="yes">β</italic> = ‐0.096 ± 0.029, <italic toggle="yes">p</italic> = 0.001) and PSMD (<italic toggle="yes">β</italic> = ‐0.085 ± 0.028, <italic toggle="yes">p</italic> = 0.002).</p></sec><sec id="alz13879-sec-0040"><title>DISCUSSION</title><p>Higher leptin bioavailability was associated with better white matter (WM) integrity in healthy middle‐aged adults, supporting the putative neuroprotective role of leptin in late‐life dementia risk.</p></sec><sec id="alz13879-sec-0050"><title>Highlights</title><p>
<list list-type="bullet" id="alz13879-list-0001"><list-item><p>Higher leptin bioavailability was related to better preservation of white matter microstructure.</p></list-item><list-item><p>Higher leptin bioavailability during midlife might confer protection against dementia.</p></list-item><list-item><p>Potential benefits might be even stronger for individuals with visceral obesity.</p></list-item><list-item><p>DTI measures might be sensitive surrogate markers of subclinical neuropathology.</p></list-item></list>
</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="alz13879-kwd-0001">cognition</kwd><kwd id="alz13879-kwd-0002">DTI</kwd><kwd id="alz13879-kwd-0003">fractional anisotropy</kwd><kwd id="alz13879-kwd-0004">free leptin index</kwd><kwd id="alz13879-kwd-0005">free water</kwd><kwd id="alz13879-kwd-0006">leptin</kwd><kwd id="alz13879-kwd-0007">leptin bioavailability</kwd><kwd id="alz13879-kwd-0008">leptin perturbations</kwd><kwd id="alz13879-kwd-0009">leptin receptor</kwd><kwd id="alz13879-kwd-0010">MarkVCID</kwd><kwd id="alz13879-kwd-0011">mean diffusivity</kwd><kwd id="alz13879-kwd-0012">MRI</kwd><kwd id="alz13879-kwd-0013">neuropsychological evaluation</kwd><kwd id="alz13879-kwd-0014">peak width of skeletonized mean diffusivity</kwd><kwd id="alz13879-kwd-0015">the Framingham Heart Study</kwd><kwd id="alz13879-kwd-0016">white matter microstructural integrity</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>National Heart Lung and Blood Institute</funding-source><award-id>N01‐HC‐25195</award-id><award-id>HHSN268201500001I</award-id><award-id>75N92019D00031</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Boston University School of Medicine
</institution><institution-id institution-id-type="doi">10.13039/100007265</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>National Institute on Aging
</institution><institution-id institution-id-type="doi">10.13039/100000049</institution-id></institution-wrap></funding-source><award-id>R01 AG054076</award-id><award-id>R01 AG049607</award-id><award-id>U01 AG052409</award-id><award-id>R01 AG059421</award-id><award-id>RF1 AG063507</award-id><award-id>RF1 AG066524</award-id><award-id>U01 AG058589</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>National Institute of Neurological Disorders and Stroke
</institution><institution-id institution-id-type="doi">10.13039/100000065</institution-id></institution-wrap></funding-source><award-id>R01 NS017950</award-id><award-id>UH2 NS100605</award-id><award-id>UF1/UH1 NS125513</award-id></award-group><award-group id="funding-0005"><funding-source>National Institute of Diabetes and Digestive and Kidney</funding-source><award-id>R01 DK080739</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="6"/><page-count count="12"/><word-count count="8496"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.9 mode:remove_FC converted:23.10.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="alz13879-cit-0068"><string-name name-style="western"><surname>Charisis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Short</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Bernal</surname><given-names>R</given-names></string-name>, et al. <article-title>Leptin bioavailability and markers of brain atrophy and vascular injury in the middle age</article-title>. <source>Alzheimer's Dement</source>. <year>2024</year>;<volume>20</volume>:<fpage>5849</fpage>–<lpage>5860</lpage>. <pub-id pub-id-type="doi">10.1002/alz.13879</pub-id><pub-id pub-id-type="pmcid">PMC11497668</pub-id><pub-id pub-id-type="pmid">39132759</pub-id></mixed-citation>
</p></notes></front><body><sec id="alz13879-sec-0060"><label>1</label><title>BACKGROUND</title><p>Alzheimer's disease (AD) is the leading cause of dementia, impacting the lives of millions of people worldwide.<xref rid="alz13879-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Accruing epidemiological evidence suggests that midlife obesity is an important contributor to the risk of developing AD.<xref rid="alz13879-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> This has created a growing interest in disentangling the mechanisms linking obesity to AD, which potentially extend through vascular,<xref rid="alz13879-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> genetic,<xref rid="alz13879-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> and metabolic pathways.<xref rid="alz13879-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>The study of adipose tissue has led to significant insights. Once viewed as a passive reservoir for energy storage, adipose tissue is now considered a part of the endocrine system, secreting a group of bioactive peptides, known as adipokines, that exert pleiotropic autocrine, paracrine, and endocrine effects in the periphery as well as the central nervous system.<xref rid="alz13879-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>
</p><p>Leptin, a cardinal adipokine responsible for central control of food intake and energy homeostasis, has been implicated in a variety of neurophysiological functions, including brain development, neurogenesis, and neuroprotection.<xref rid="alz13879-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Due to these effects, it has been considered a plausible mechanistic intermediary in the pathway leading from obesity to AD. This hypothesis has been substantiated by findings relating higher leptin levels to lower risk for incident AD and mild cognitive impairment (MCI),<xref rid="alz13879-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="alz13879-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> as well as better structural brain indices in older adults.<xref rid="alz13879-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> However, studies conducted in younger individuals have not detected associations between leptin and late‐life dementia risk or AD endophenotypes, such as neuropsychological test scores or brain volume measures.<xref rid="alz13879-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="alz13879-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Given the long latency period between the onset of pathological changes in the brain and the manifestation of clinical symptoms that characterize AD,<xref rid="alz13879-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> these incongruent findings could indicate that decreased leptin levels might actually represent a consequence rather than a cause of AD‐related pathobiological processes. This highlights the importance of studying the associations of leptin markers with cognitive and neuroimaging outcomes in younger individuals, who are less likely to have accumulated AD pathology.</p><p>Important to consider is also the fact that in certain individuals, particularly those who are obese, high levels of circulating leptin might be linked to the development of central leptin resistance, ultimately reflecting a state of relative leptin deficiency from a brain‐signaling standpoint.<xref rid="alz13879-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Measuring the free leptin index (FLI) has been proposed as a way to account for leptin resistance and reflect leptin bioavailability<xref rid="alz13879-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz13879-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz13879-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>; therefore, FLI might be more sensitive than circulating leptin levels to capture potential relationships between leptin signaling states and health‐related outcomes.</p><p>In the present study, we aimed to gain further insights into the potential relationships of leptin with neurodegenerative and cerebrovascular burden. To this end, we investigated the associations of leptin, its soluble receptor, and leptin bioavailability with cognitive function and magnetic resonance imaging (MRI) markers of brain atrophy and vascular injury in cognitively healthy, community‐dwelling middle‐aged adults from the Framingham Heart Study (FHS). We further sought replication in a diverse cohort of the MarkVCID study.</p></sec><sec id="alz13879-sec-0070"><label>2</label><title>METHODS</title><sec id="alz13879-sec-0080"><label>2.1</label><title>Participants</title><p>The present cross‐sectional investigation included cognitively healthy participants from the Third Generation Cohort of the FHS,<xref rid="alz13879-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> who provided blood samples at the first examination cycle (2002–2005) and underwent brain MRI and neuropsychological testing at the second examination cycle (2008–2011). Those with missing data on demographic characteristics or cardiovascular risk factors were excluded. Furthermore, participants with a contraindication for MRI, stroke by the time of MRI acquisition, or other neurological findings that could substantially influence the measurement of MRI outcomes were excluded from MRI analyses. The final analytic sample consisted of 2262 participants for neurocognitive analyses, and 2028 participants for MRI analyses (Figure <xref rid="alz13879-fig-0001" ref-type="fig">1</xref>). All participants have provided written informed consent. Study protocols and consent forms have been approved by the institutional review board of the Boston University Medical Center.</p><fig position="float" fig-type="FIGURE" id="alz13879-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Flowchart of the Framingham Heart Study (FHS) sample.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="ALZ-20-5849-g001.jpg"/></fig></sec><sec id="alz13879-sec-0090"><label>2.2</label><title>Measurement of leptin markers</title><p>Blood samples were collected after an overnight fast and were stored at ‐80°C until processing. The concentrations of leptin and soluble leptin receptor (sOB‐R) were measured from serum using a standard enzyme‐linked immunosorbent assay (ELISA). The intra‐assay coefficients of variation were 4.97% for the leptin assay and 4.01% for the sOB‐R assay.<xref rid="alz13879-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> The FLI was calculated as the ratio of leptin to sOB‐R. Higher FLI values indicate greater leptin bioavailability.<xref rid="alz13879-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="alz13879-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="alz13879-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p></sec><sec id="alz13879-sec-0100"><label>2.3</label><title>Neuropsychological evaluation</title><p>Cognitive function was assessed with a neuropsychological test battery consisting of validated tests, designed to evaluate different cognitive domains. The following cognitive domains were assessed (using the respective tests): abstract reasoning (Wechsler Adult Intelligence Scale [WAIS] similarities test), processing speed (Trail Making Test‐TMT part A [TMT‐A]), executive functioning (TMT part B [TMT‐B]), episodic memory (logical memory delayed recall), and visuospatial skills (Hooper Visual Organization Test [HVOT]). TMT‐A and TMT‐B scores were multiplied by ‐1 for better interpretability (i.e., higher scores reflect better cognitive performance).</p></sec><sec id="alz13879-sec-0110"><label>2.4</label><title>Neuroimaging indices</title><p>Study participants underwent brain MRI on a variety of machines with 1.5 Tesla field strength. The detailed brain MRI protocol has been described elsewhere.<xref rid="alz13879-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Briefly, three‐dimensional T1‐weighted, fluid‐attenuated inversion recovery (FLAIR), and diffusion tensor imaging (DTI) sequences were obtained. Total brain, cortical gray matter, hippocampal, and white matter hyperintensity (WMH) volumes were derived using standard protocols.<xref rid="alz13879-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Total cranial volume (TCV) was determined using a convolutional neural network method.<xref rid="alz13879-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Volumetric measures were divided by TCV to correct for head size.</p><boxed-text position="float" content-type="box" orientation="portrait"><sec id="alz13879-sec-0120"><title>RESEARCH IN CONTEXT</title><p>
<list list-type="order" id="alz13879-list-0002"><list-item><p>
<bold>Systematic review</bold>: The literature was reviewed using traditional (e.g., PubMed) sources. Leptin perturbations have been associated with dementia and cognitive decline in older adults. However, due to the long preclinical stages that characterize these disorders, previous findings might be confounded by reverse causality.</p></list-item><list-item><p>
<bold>Interpretation</bold>: Our findings suggest that higher leptin bioavailability during midlife is related to better preservation of white matter microstructure, and therefore, it might confer protection against the development of cognitive decline and dementia later in life by maintaining cognitive network efficiency.</p></list-item><list-item><p>
<bold>Future directions</bold>: This study provides insights into the putative neuroprotective role of leptin in late‐life dementia risk. Interventions that correct leptin perturbations during midlife might be important strategies for dementia risk reduction and should be further studied, ideally, through clinical trials.</p></list-item></list>
</p></sec></boxed-text><p>White matter (WM) microstructural integrity measures of free water (FW), free water‐corrected fractional anisotropy (FA), and peak width of skeletonized mean diffusivity (PSMD) were derived from DTI sequences using previously described algorithms.<xref rid="alz13879-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz13879-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz13879-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Briefly, FW and FA were derived from the WM mask, which was defined by thresholding the FSL FA template at a value of 0.3 to reduce cerebrospinal fluid (CSF) partial volume contamination.<xref rid="alz13879-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="alz13879-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> PSMD was calculated using a publicly available script (PSMD Marker,<xref rid="alz13879-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> version 0.95), as the difference between the 95th and 5th percentiles of the voxel‐based mean diffusivity (MD) values within the subject's MD skeleton, after application of FA threshold and custom‐made masks to avoid contamination of the skeleton by CSF partial volume effects.<xref rid="alz13879-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz13879-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> The rationale for selecting the above‐mentioned DTI measures was twofold. First, their inter‐rater reliability, test‐retest repeatability, and inter‐scanner reproducibility have been previously explored and ascertained.<xref rid="alz13879-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Second, the used algorithms for FA and PSMD calculation account for CSF contamination of the diffusion signal, to provide tissue‐specific DTI indices and consequently allow for more accurate inferences about the underlying WM tissue structure. <xref rid="alz13879-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="alz13879-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="alz13879-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p></sec><sec id="alz13879-sec-0130"><label>2.5</label><title>Cardiovascular risk factors and other covariates</title><p>All participants undergo standardized assessments at each examination cycle, where anthropometric measurements are obtained, and information regarding medication records and clinical history are updated. Diabetes mellitus (DM) was defined by either a fasting blood glucose of ≥126 mg/dL, or the use of glucose‐lowering medications. Body mass index (BMI) was calculated as weight divided by the height squared (kg/m<sup>2</sup>). Systolic blood pressure (SBP) was derived from the average of 2 blood pressure readings obtained 10 min apart with the participant resting in a sitting position. Smoking was defined as current smoking within the year preceding the assessment. Waist‐to‐hip ratio (WHR) was calculated by dividing the participant's waist circumference by hip circumference (cm/cm), and was ranked into quartiles within the individual sex groups; subsequently, WHR was dichotomized by the upper quartile (WHR &gt; 1.01 for men and WHR &gt; 0.92 for women) to indicate excess WHR. Prevalent cardiovascular disease (CVD) was defined as a positive history of transient ischemic attack, coronary heart disease, congestive heart failure, or peripheral vascular disease.</p></sec><sec id="alz13879-sec-0140"><label>2.6</label><title>Statistical analysis</title><p>Continuous variable distributions were graphically explored using Q‐Q plots. The variables expressing serum leptin concentration, serum sOB‐R concentration, FLI, WMH volume, FW, PSMD, TMT‐A, TMT‐B, and HVOT scores were natural log‐transformed to normalize their distributions. Subsequently, the natural log‐transformed leptin marker variables were standardized within sex to account for differences in their distributions between men and women.<xref rid="alz13879-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><sec id="alz13879-sec-0150"><label>2.6.1</label><title>Primary analyses</title><p>Associations of leptin markers with cognitive and MRI indices were explored using linear regression models with the respective neuropsychological or brain imaging measure of interest as the outcome and leptin markers as the main predictors (in separate models for each marker). Models were adjusted for age, sex, BMI, DM, SBP, antihypertensive medication use, smoking, prevalent CVD, and the time interval between blood draw and neuropsychological evaluation or brain MRI acquisition. Cognitive models were further adjusted for educational attainment; MRI models including DTI‐derived outcomes were further adjusted for TCV to account for potential influences of head size on DTI measures.<xref rid="alz13879-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p><p>The false discovery rate (FDR) was controlled at &lt; 5% using the Benjamini‐Hochberg procedure to account for multiple hypothesis testing,<xref rid="alz13879-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> with cognitive and MRI outcomes considered separately.</p></sec><sec id="alz13879-sec-0160"><label>2.6.2</label><title>Replication</title><p>To examine the replicability and external validity of primary analysis findings, we used data from the MarkVCID‐1 study. MarkVCID‐1 was established as a consortium of 7 sites across the United States, aiming to identify and validate fluid‐ and MRI‐based biomarkers for vascular injury associated with vascular contributions to cognitive impairment and dementia (VCID).<xref rid="alz13879-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> This replication analysis includes data from the San Antonio site with Olink Explore panel and neurological outcome data (imaging and cognitive) measured at the baseline visit (version dated January 17, 2022). Specifically, significant associations of leptin makers with cognitive or MRI outcomes in FHS were also assessed in a sample of 89 dementia‐free Mexican American participants. The standardized clinical, imaging, and biobanking protocols of the MarkVCID‐1 study have been described elsewhere.<xref rid="alz13879-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="alz13879-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Briefly, MRI measures were derived using similar protocols to the FHS cohort.<xref rid="alz13879-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Processing speed and executive functioning were assessed similarly to the FHS (using the TMT‐A and TMT‐B tests, respectively), and episodic memory was assessed with the Craft Story 21 Recall (Delayed).<xref rid="alz13879-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The similarities and HVOT tests were not part of the MarkVCID‐1 neuropsychological test battery. Leptin and leptin receptor measurements were derived from the Olink cardiometabolic panel (included as part of the Explore panel). Olink assays report protein levels in a proprietary relative quantification unit, called Normalized Protein eXpression (NPX), that is not directly comparable between different proteins/analytes. Algorithms that convert these values to conventional protein concentration units are not available; therefore, FLI calculation was not feasible. However, here we report results for leptin and leptin receptor, with the latter representing an indirect measure of leptin bioavailability. Because NPX is in a log<sub>2</sub> scale, a 1 NPX difference can be interpreted as a doubling of protein concentration. Models were similarly structured to those described in Section 2.6.1, and were adjusted for age, sex, BMI, DM, SBP, antihypertensive medication use, smoking, and TCV.</p></sec><sec id="alz13879-sec-0170"><label>2.6.3</label><title>Exploratory analyses</title><p>Considering that leptin expression in humans exhibits sexual dimorphism and prior findings suggesting that obesity might influence the relationships between leptin and cognitive function,<xref rid="alz13879-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="alz13879-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz13879-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> we tested for interactions between leptin markers and sex or excess WHR on neurological outcomes in secondary analyses. A two‐step approach was followed. First, as an omnibus test, the product term of the respective leptin marker and the moderator of interest (M) was entered in a model including the same set of confounders as the primary analyses, as well as M by confounder interaction terms. If the product term was significant at <italic toggle="yes">p</italic> ≤0 .1, then potential effect modification by M was further explored by conducting stratified analysis at the different levels of M; M was considered an effect modifier if stratified analysis for the association of interest indicated either the presence of a significant association in one stratum but not the other, or significant associations in both strata with different stratum‐specific estimates.<xref rid="alz13879-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>Statistical analyses were performed using SAS Software, version 9.4 (SAS Institute). A 2‐sided <italic toggle="yes">p</italic>‐value &lt; 0.05 was considered statistically significant.</p></sec></sec></sec><sec id="alz13879-sec-0180"><label>3</label><title>RESULTS</title><sec id="alz13879-sec-0190"><label>3.1</label><title>Participant characteristics in FHS</title><p>Participant characteristics of the FHS sample are presented in Table <xref rid="alz13879-tbl-0001" ref-type="table">1</xref>. In the largest (cognitive) sample, the mean age was 40.4 (standard deviation [SD] = 8.6) years, and 1186 (52.4%) participants were women. Most participants (&gt; 99%) were non‐Hispanic Whites. Current smoking and use of antihypertensive medications were reported by 13.2% and 7.7% of study participants, respectively. The prevalence of DM was 2.6%, and of CVD 0.9%. The mean SBP was 116.9 (SD = 13.9), and the mean BMI was 26.9 (SD = 5.4). The MRI sample displayed similar characteristics, although with a slightly better cardiovascular profile.</p><table-wrap position="float" id="alz13879-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Participant characteristics in the Framingham Heart Study.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Demographic, anthropometric, and clinical characteristics</th><th align="left" rowspan="1" colspan="1">NP sample (<italic toggle="yes">n</italic> = 2262)</th><th align="left" rowspan="1" colspan="1">MRI sample (<italic toggle="yes">n</italic> = 2028)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Women</td><td align="char" rowspan="1" colspan="1">1186 (52.4)</td><td align="char" rowspan="1" colspan="1">1070 (52.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Men</td><td align="char" rowspan="1" colspan="1">1076 (47.6)</td><td align="char" rowspan="1" colspan="1">958 (47.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">40.4 (8.6)</td><td align="char" rowspan="1" colspan="1">40.2 (8.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Black</td><td align="char" rowspan="1" colspan="1">3 (0.1)</td><td align="char" rowspan="1" colspan="1">3 (0.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">White</td><td align="char" rowspan="1" colspan="1">2251 (99.5)</td><td align="char" rowspan="1" colspan="1">2018 (99.5)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Other</td><td align="char" rowspan="1" colspan="1">8 (0.4)</td><td align="char" rowspan="1" colspan="1">7 (0.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hispanic</td><td align="char" rowspan="1" colspan="1">2 (0.1)</td><td align="char" rowspan="1" colspan="1">2 (0.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Non‐Hispanic</td><td align="char" rowspan="1" colspan="1">2260 (99.9)</td><td align="char" rowspan="1" colspan="1">2026 (99.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Bachelor's degree</td><td align="char" rowspan="1" colspan="1">843 (37.3)</td><td align="char" rowspan="1" colspan="1">767 (37.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Graduate degree</td><td align="char" rowspan="1" colspan="1">380 (16.8)</td><td align="char" rowspan="1" colspan="1">347 (17.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Highschool or less</td><td align="char" rowspan="1" colspan="1">310 (13.7)</td><td align="char" rowspan="1" colspan="1">268 (13.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Some college</td><td align="char" rowspan="1" colspan="1">729 (32.2)</td><td align="char" rowspan="1" colspan="1">640 (31.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood draw to NP or MRI interval, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">7.8 (1.1)</td><td align="char" rowspan="1" colspan="1">7.8 (1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">26.9 (5.4)</td><td align="char" rowspan="1" colspan="1">26.7 (5.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">WHR, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.92 (0.08)</td><td align="char" rowspan="1" colspan="1">0.92 (0.08)</td></tr><tr><td align="left" rowspan="1" colspan="1">Excess WHR, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">No</td><td align="char" rowspan="1" colspan="1">1705 (75.5)</td><td align="char" rowspan="1" colspan="1">1543 (76.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Yes</td><td align="char" rowspan="1" colspan="1">553 (24.5)</td><td align="char" rowspan="1" colspan="1">483 (23.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg, mean (SD)</td><td align="char" rowspan="1" colspan="1">116.9 (13.9)</td><td align="char" rowspan="1" colspan="1">116.7 (13.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antihypertensive medication use, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">174 (7.7)</td><td align="char" rowspan="1" colspan="1">156 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">58 (2.6)</td><td align="char" rowspan="1" colspan="1">50 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">299 (13.2)</td><td align="char" rowspan="1" colspan="1">257 (12.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prevalent cardiovascular disease <xref rid="alz13879-tbl1-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">20 (0.9)</td><td align="char" rowspan="1" colspan="1">14 (0.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin markers</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Leptin, ng/mL, median (IQR)</td><td align="char" rowspan="1" colspan="1">7280 (3645, 14,973)</td><td align="char" rowspan="1" colspan="1">7330 (3623, 14,861)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">sOB‐R, ng/mL, median (IQR)</td><td align="char" rowspan="1" colspan="1">17.7 (12.1, 23.7)</td><td align="char" rowspan="1" colspan="1">18.2 (12.3, 24.1)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">FLI, median (IQR)</td><td align="char" rowspan="1" colspan="1">423.0 (193.5, 970.1)</td><td align="char" rowspan="1" colspan="1">418.3 (188.4, 961.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropsychological test scores</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Similarities, mean (SD)</td><td align="char" rowspan="1" colspan="1">17.34 (3.06)</td><td align="char" rowspan="1" colspan="1">17.36 (3.09)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part A, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.40 (0.32, 0.48)</td><td align="char" rowspan="1" colspan="1">0.38 (0.32, 0.47)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part B, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.93 (0.75, 1.18)</td><td align="char" rowspan="1" colspan="1">0.93 (0.75, 1.17)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Logical memory delayed recall, mean (SD)</td><td align="char" rowspan="1" colspan="1">11.79 (3.58)</td><td align="char" rowspan="1" colspan="1">11.79 (3.59)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HVOT, median (IQR)</td><td align="char" rowspan="1" colspan="1">27.0 (25.5, 28.0)</td><td align="char" rowspan="1" colspan="1">27.0 (25.5, 28.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">MRI measures (<italic toggle="yes">n</italic> = 2129)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total cranial volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">1264.1 (125.3)</td><td align="char" rowspan="1" colspan="1">1263.1 (125.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total brain volume, cm<sup>3</sup>, mean (SD)1</td><td align="char" rowspan="1" colspan="1">998.4 (102.6)</td><td align="char" rowspan="1" colspan="1">997.9 (102.8)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cortical gray matter volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">480.2 (46.6)</td><td align="char" rowspan="1" colspan="1">480.0 (46.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Hippocampal volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">6.86 (0.72)</td><td align="char" rowspan="1" colspan="1">6.86 (0.72)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">WMH volume, cm<sup>3</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.42 (0.21, 0.88)</td><td align="char" rowspan="1" colspan="1">0.42 (0.21, 0.86)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Fractional anisotropy, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.62 (0.01)</td><td align="char" rowspan="1" colspan="1">0.63 (0.01)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Free water, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.20 (0.19, 0.21)</td><td align="char" rowspan="1" colspan="1">0.20 (0.19, 0.21)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PSMD × 10<sup>−4</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">2.16 (2.01, 2.36)</td><td align="char" rowspan="1" colspan="1">2.16 (2.01, 2.36)</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl1-note-0002"><p>Abbreviations: BMI, body mass index; FLI, free leptin index; HVOT, Hooper Visual Organization Test.; IQR, interquartile range; MRI, magnetic resonance imaging; NP, neuropsychological evaluation; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; sOB‐R, soluble leptin receptor; TMT, Trail Making Test; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity.</p></fn><fn id="alz13879-tbl1-note-0001"><label>
<sup>a</sup>
</label><p>Prevalent cardiovascular disease includes history of transient ischemic attack, coronary heart disease, congestive heart failure, or peripheral vascular disease.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz13879-sec-0200"><label>3.2</label><title>Primary analyses</title><sec id="alz13879-sec-0210"><label>3.2.1</label><title>Associations with cognitive measures</title><p>Associations of leptin markers with neuropsychological test scores in the FHS are presented in Table <xref rid="alz13879-tbl-0002" ref-type="table">2</xref>. For the reported associations in which the response variable was log‐transformed, the respective beta coefficients can be interpreted as indicating the relative change in the response variable for an increase in the predictor variable by 1 SD unit (i.e., in a model of the form <mml:math id="jats-math-1" display="inline"><mml:mrow><mml:mrow><mml:mi>ln</mml:mi><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mspace width="0.33em"/><mml:mo>×</mml:mo><mml:mi>χ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>, for a one‐increment increase in <mml:math id="jats-math-2" display="inline"><mml:mrow><mml:mi>χ</mml:mi></mml:mrow></mml:math>, the relative change in <mml:math id="jats-math-3" display="inline"><mml:mrow><mml:mi>y</mml:mi></mml:mrow></mml:math> is equal to <mml:math id="jats-math-4" display="inline"><mml:mrow><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:msup><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math>, which can be approximated to <mml:math id="jats-math-5" display="inline"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math> for values of <mml:math id="jats-math-6" display="inline"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math> close to zero, using the first two terms of a Maclaurin series expansion). Although there were nominal associations of higher FLI with worse performance in TMT‐A and better performance in the logical memory delayed recall, these did not remain significant after correction for multiple testing (Table <xref rid="alz13879-tbl-0002" ref-type="table">2</xref>). Relationships between leptin markers and other neuropsychological test scores were not significant.</p><table-wrap position="float" id="alz13879-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Associations of leptin markers with neuropsychological test scores (<italic toggle="yes">n</italic> = 2262).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Leptin<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">sOB‐R<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">FLI<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Cognitive outcome</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Similarities</td><td align="char" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.90</td><td align="char" rowspan="1" colspan="1">−0.001</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="char" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">TMT part A<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>, <xref rid="alz13879-tbl2-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">−0.057</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">0.036</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="char" rowspan="1" colspan="1">−0.068</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">TMT part B<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>, <xref rid="alz13879-tbl2-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="char" rowspan="1" colspan="1">−0.018</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.40</td><td align="char" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Logical memory delayed recall</td><td align="char" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">−0.029</td><td align="left" rowspan="1" colspan="1">0.021</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="char" rowspan="1" colspan="1">0.062</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">HVOT<xref rid="alz13879-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.032</td><td align="left" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.30</td><td align="char" rowspan="1" colspan="1">−0.011</td><td align="left" rowspan="1" colspan="1">0.022</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="left" rowspan="1" colspan="1">0.029</td><td align="left" rowspan="1" colspan="1">0.29</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl2-note-0001"><p>
<italic toggle="yes">Note</italic>: Results from linear regression models with the respective neuropsychological test score as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment. Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and raw <italic toggle="yes">p</italic>‐values (<italic toggle="yes">p</italic>). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.</p></fn><fn id="alz13879-tbl2-note-0004"><p>Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test.;sOB‐R, soluble leptin receptor; TMT, Trail Making Test.</p></fn><fn id="alz13879-tbl2-note-0002"><label>
<sup>a</sup>
</label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl2-note-0003"><label>
<sup>b</sup>
</label><p>Scores were multiplied by −1 so that higher scores reflect better cognitive performance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz13879-sec-0220"><label>3.2.2</label><title>Associations with MRI measures</title><p>Associations of leptin markers with MRI markers of brain atrophy and vascular injury in the FHS are presented in Table <xref rid="alz13879-tbl-0003" ref-type="table">3</xref>. No associations were observed between serum leptin concentrations and MRI indices. An increase in ln(sOB‐R) concentrations by 1 SD was associated with a 0.11‐unit decrease in FA (<italic toggle="yes">β</italic> = ‐0.114, standard error [SE] = 0.02, <italic toggle="yes">p</italic> &lt; 0.001), a 9.1% increase in FW (<italic toggle="yes">β</italic> = 0.091, SE = 0.022, <italic toggle="yes">p</italic> &lt; 0.001), and a 7.8% increase in PSMD (<italic toggle="yes">β</italic> = 0.078, SE = 0.021, <italic toggle="yes">p</italic> &lt; 0.001), indicating overall worse WM microstructural integrity. Correspondingly, a 1 SD increase in ln(FLI), reflecting an increase in the concentration of bioavailable leptin, was associated with a 0.12‐unit increase in FA (<italic toggle="yes">β</italic> = 0.115, SE = 0.027, <italic toggle="yes">p</italic> &lt; 0.001), a 9.6% decrease in FW (<italic toggle="yes">β</italic> = ‐0.096, SE = 0.029, <italic toggle="yes">p</italic> = 0.001), and a 8.5% decrease in PSMD (<italic toggle="yes">β</italic> = ‐0.085, SE = 0.028, <italic toggle="yes">p</italic> = 0.002), indicating overall better WM microstructural integrity. These associations remained significant after correction for multiple testing. Nominal associations of lower sOB‐R concentrations and higher FLI with lower WMH volume were also observed but did not survive correction for multiple testing.</p><table-wrap position="float" id="alz13879-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Associations of leptin markers with MRI markers of brain atrophy and vascular injury (<italic toggle="yes">n</italic> = 2028).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Leptin<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">sOB‐R<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">FLI<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">MRI outcome</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">β</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total brain volume<xref rid="alz13879-tbl3-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.008</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.78</td><td align="char" rowspan="1" colspan="1">−0.013</td><td align="char" rowspan="1" colspan="1">0.020</td><td align="char" rowspan="1" colspan="1">0.52</td><td align="char" rowspan="1" colspan="1">0.016</td><td align="char" rowspan="1" colspan="1">0.027</td><td align="char" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Cortical gray matter volume<xref rid="alz13879-tbl3-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.023</td><td align="char" rowspan="1" colspan="1">0.028</td><td align="char" rowspan="1" colspan="1">0.41</td><td align="char" rowspan="1" colspan="1">−0.009</td><td align="char" rowspan="1" colspan="1">0.020</td><td align="char" rowspan="1" colspan="1">0.66</td><td align="char" rowspan="1" colspan="1">0.022</td><td align="char" rowspan="1" colspan="1">0.026</td><td align="char" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Hippocampal volume<xref rid="alz13879-tbl3-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.011</td><td align="char" rowspan="1" colspan="1">0.033</td><td align="char" rowspan="1" colspan="1">0.73</td><td align="char" rowspan="1" colspan="1">−0.012</td><td align="char" rowspan="1" colspan="1">0.024</td><td align="char" rowspan="1" colspan="1">0.62</td><td align="char" rowspan="1" colspan="1">0.017</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="char" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1">WMH volume<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>, <xref rid="alz13879-tbl3-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">−0.034</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.24</td><td align="char" rowspan="1" colspan="1">0.040</td><td align="char" rowspan="1" colspan="1">0.021</td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">−0.054</td><td align="char" rowspan="1" colspan="1">0.027</td><td align="char" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Fractional anisotropy<xref rid="alz13879-tbl3-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.041</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.16</td><td align="char" rowspan="1" colspan="1">
<bold>−0.114</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.020</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.115</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.027</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Free water<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>, <xref rid="alz13879-tbl3-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">−0.039</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="char" rowspan="1" colspan="1">0.21</td><td align="char" rowspan="1" colspan="1">
<bold>0.091</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>−0.096</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.029</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">PSMD<xref rid="alz13879-tbl3-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>, <xref rid="alz13879-tbl3-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">−0.038</td><td align="char" rowspan="1" colspan="1">0.029</td><td align="char" rowspan="1" colspan="1">0.20</td><td align="char" rowspan="1" colspan="1">
<bold>0.078</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.021</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>−0.085</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.028</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl3-note-0001"><p>
<italic toggle="yes">Note</italic>: Results from linear regression models with the respective MRI marker as the outcome and the respective leptin marker as the main predictor. Models are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition. Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and raw <italic toggle="yes">p</italic> values (<italic toggle="yes">p</italic>). Statistically significant findings after false discovery rate control at 5% using the Benjamini‐Hochberg procedure are indicated in bold.</p></fn><fn id="alz13879-tbl3-note-0005"><p>Abbreviations: FLI, free leptin index, MRI, magnetic resonance imaging; PSMD, peak width of skeletonized mean diffusivity.; sOB‐R, soluble leptin receptor; WMH, white matter hyperintensity.</p></fn><fn id="alz13879-tbl3-note-0002"><label>
<sup>a</sup>
</label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl3-note-0003"><label>
<sup>b</sup>
</label><p>as percentage of total cranial volume.</p></fn><fn id="alz13879-tbl3-note-0004"><label>
<sup>c</sup>
</label><p>Models are further adjusted for total cranial volume.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="alz13879-sec-0230"><label>3.3</label><title>Replication</title><p>Participant characteristics of the MarkVCID‐1 sample are presented in Table <xref rid="alz13879-tbl-0004" ref-type="table">4</xref>. Mean age was 70.5 (SD = 7.3) years, and 66 (74.2%) study participants were women. Overall, prevalence of cardiovascular risk factors, including use of antihypertensive medications (51.7%), diabetes (27%), and current smoking (24.7%), was higher compared to the FHS sample. Mean SBP (134.2, SD = 17.9) and BMI (30.3, SD = 6.4) were also higher.</p><table-wrap position="float" id="alz13879-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Participant characteristics in the MarkVCID‐1 sample (<italic toggle="yes">n</italic> = 89).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Demographic, anthropometric, and clinical characteristics</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Women</td><td align="char" rowspan="1" colspan="1">66 (74.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Men</td><td align="char" rowspan="1" colspan="1">23 (25.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">70.5 (7.3)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Education, years, mean (SD)</td><td align="char" rowspan="1" colspan="1">14.3 (2.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">30.3 (6.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg, mean (SD)</td><td align="char" rowspan="1" colspan="1">134.2 (17.9)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Antihypertensive medication use, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">46 (51.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">24 (27.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Current smoking, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">22 (24.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Leptin markers</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Leptin, NPX, mean (SD)</td><td align="char" rowspan="1" colspan="1">−0.2 (1.4)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Leptin receptor, NPX, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.1 (0.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neuropsychological test scores</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part A, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.57 (0.43, 0.70)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part B, min, median (IQR)</td><td align="char" rowspan="1" colspan="1">1.49 (1.21, 2.29)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Craft Story 21 Recall (Delayed), mean (SD)</td><td align="char" rowspan="1" colspan="1">17.2 (6.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">MRI measures</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total cranial volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">1349.8 (142.0)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total brain volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">1049.2 (109.7)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total gray matter volume, cm<sup>3</sup>, mean (SD)</td><td align="char" rowspan="1" colspan="1">582.8 (54.2)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">WMH volume, cm<sup>3</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">1.91 (0.87, 3.22)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Fractional anisotropy, mean (SD)</td><td align="char" rowspan="1" colspan="1">0.50 (0.01)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Free water, median (IQR)</td><td align="char" rowspan="1" colspan="1">0.18 (0.17, 0.21)</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PSMD × 10<sup>−4</sup>, median (IQR)</td><td align="char" rowspan="1" colspan="1">3.25 (2.94, 3.49)</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl4-note-0001"><p>Abbreviations: BMI, body mass index; IQR, interquartile range; MRI, magnetic resonance imaging; NPX, Normalized Protein eXpression; PSMD, peak width of skeletonized mean diffusivity; SD, standard deviation; TMT, Trail Making Test.; WMH, white matter hyperintensity.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>A twofold increase in leptin receptor concentration was associated with a 10% increase in PSMD (<italic toggle="yes">β</italic> = 0.099, SE = 0.031, <italic toggle="yes">p</italic> = 0.002). No associations were observed with FA (<italic toggle="yes">β</italic> = ‐0.002, SE = 0.004, <italic toggle="yes">p</italic> = 0.64) or FW (<italic toggle="yes">β</italic> = 0.034, SE = 0.036, <italic toggle="yes">p</italic> = 0.36).</p></sec><sec id="alz13879-sec-0240"><label>3.4</label><title>Exploratory analyses</title><sec id="alz13879-sec-0250"><label>3.4.1</label><title>Interaction and effect modification by sex</title><p>Interaction and effect modification analyses for sex are presented in Table <xref rid="alz13879-supitem-0001" ref-type="supplementary-material">S1</xref> and Table <xref rid="alz13879-tbl-0005" ref-type="table">5</xref>, respectively. The product terms of all leptin markers with sex were significant in models with HVOT score as the outcome, suggesting the potential presence of interaction. Stratified analyses revealed that in men, a 1 SD increase in ln(Leptin) concentration was associated with an 11.2% increase in HVOT scores (<italic toggle="yes">β</italic> = 0.112, SE = 0.047, <italic toggle="yes">p</italic> = 0.02), and a 1 SD increase in ln(FLI) was associated with a 12.3% increase in HVOT scores (<italic toggle="yes">β</italic> = 0.123, SE = 0.044, <italic toggle="yes">p</italic> = 0.006); these associations were not present in women or the total sample. In addition, the product term of FLI with sex was significant in models with TMT‐B score as the outcome. In stratified analyses, a 1 SD increase in ln(FLI) was associated with a 9.2% increase in TMT‐B scores in men (<italic toggle="yes">β</italic> = 0.092, SE = 0.044, <italic toggle="yes">p</italic> = 0.04), whereas no such association was observed in women or the total sample. Finally, although the omnibus test was significant, suggesting a potential interaction between leptin concentration and sex on total brain volume, no significant associations were detected in stratified analyses.</p><table-wrap position="float" id="alz13879-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Associations of leptin markers with MRI and cognitive outcomes in different sex subgroups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Men<xref rid="alz13879-tbl5-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">Women<xref rid="alz13879-tbl5-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Leptin marker</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for interaction<xref rid="alz13879-tbl5-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="char" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MRI outcomes<xref rid="alz13879-tbl5-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">
<italic toggle="yes">n</italic> = 958</td><td colspan="3" align="left" rowspan="1">
<italic toggle="yes">n</italic> = 1070</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Total brain volume<xref rid="alz13879-tbl5-note-0005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Leptin<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.05</td><td align="char" rowspan="1" colspan="1">0.066</td><td align="char" rowspan="1" colspan="1">0.042</td><td align="char" rowspan="1" colspan="1">0.11</td><td align="char" rowspan="1" colspan="1">−0.045</td><td align="char" rowspan="1" colspan="1">0.040</td><td align="char" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognitive outcome<xref rid="alz13879-tbl5-note-0007" ref-type="table-fn">
<sup>f</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">
<italic toggle="yes">n</italic> = 1076</td><td colspan="3" align="left" rowspan="1">
<italic toggle="yes">n</italic> = 1186</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HVOT<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Leptin<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">
<bold>0.112</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.047</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="char" rowspan="1" colspan="1">−0.016</td><td align="char" rowspan="1" colspan="1">0.040</td><td align="char" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">sOB‐R<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">−0.058</td><td align="char" rowspan="1" colspan="1">0.034</td><td align="char" rowspan="1" colspan="1">0.09</td><td align="char" rowspan="1" colspan="1">0.032</td><td align="char" rowspan="1" colspan="1">0.028</td><td align="char" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FLI<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.007</td><td align="char" rowspan="1" colspan="1">
<bold>0.123</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.044</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.006</bold>
</td><td align="char" rowspan="1" colspan="1">−0.036</td><td align="char" rowspan="1" colspan="1">0.038</td><td align="char" rowspan="1" colspan="1">0.35</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">TMT part B<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>, <xref rid="alz13879-tbl5-note-0008" ref-type="table-fn">
<sup>g</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">FLI<xref rid="alz13879-tbl5-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.1</td><td align="char" rowspan="1" colspan="1">
<bold>0.092</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.044</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="char" rowspan="1" colspan="1">−0.004</td><td align="char" rowspan="1" colspan="1">0.038</td><td align="char" rowspan="1" colspan="1">0.93</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl5-note-0001"><p>
<italic toggle="yes">Note</italic>: Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and <italic toggle="yes">p</italic>‐values (<italic toggle="yes">p</italic>). Statistically significant findings at <italic toggle="yes">p</italic> ≤0.05 are indicated in bold.</p></fn><fn id="alz13879-tbl5-note-0009"><p>Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor.</p></fn><fn id="alz13879-tbl5-note-0002"><label>
<sup>a</sup>
</label><p>Linear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker, sex, as well as their product term as the main predictors. Values represent the <italic toggle="yes">p</italic>‐value of the respective product term (<italic toggle="yes">p</italic> for interaction). Only significant findings at <italic toggle="yes">p</italic> ≤0.1 are presented.</p></fn><fn id="alz13879-tbl5-note-0003"><label>
<sup>b</sup>
</label><p>Linear regression models with the respective MRI marker or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted by sex subgroups.</p></fn><fn id="alz13879-tbl5-note-0004"><label>
<sup>c</sup>
</label><p>Models are adjusted for age, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.</p></fn><fn id="alz13879-tbl5-note-0005"><label>
<sup>d</sup>
</label><p>as percentage of total cranial volume.</p></fn><fn id="alz13879-tbl5-note-0006"><label>
<sup>e</sup>
</label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl5-note-0007"><label>
<sup>f</sup>
</label><p>Models are adjusted for age, education, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and neuropsychological assessment.</p></fn><fn id="alz13879-tbl5-note-0008"><label>
<sup>g</sup>
</label><p>Scores were multiplied by ‐1 so that higher scores reflect better cognitive performance.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="alz13879-sec-0260"><label>3.4.2</label><title>Interaction and effect modification by WHR</title><p>Interaction and effect modification analyses for WHR are presented in Table <xref rid="alz13879-supitem-0001" ref-type="supplementary-material">S2</xref> and Table <xref rid="alz13879-tbl-0006" ref-type="table">6</xref>, respectively. The product terms of WHR with sOB‐R and FLI were significant in models with PSMD as the outcome. Stratified analyses revealed that the effect size for the association of sOB‐R with PSMD was larger in participants with excess WHR compared to those without excess WHR as well as the total sample. Moreover, the association of higher FLI with lower PSMD observed in the total sample was only present in participants with excess WHR.</p><table-wrap position="float" id="alz13879-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Associations of leptin markers with MRI and cognitive outcomes in different WHR subgroups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">WHR Q<sub>1</sub>‐Q<sub>3</sub>
<xref rid="alz13879-tbl6-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th colspan="3" style="border-bottom:solid 1px #000000" align="left" rowspan="1">WHR Q<sub>4</sub>
<xref rid="alz13879-tbl6-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Leptin marker</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> for interaction<xref rid="alz13879-tbl6-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">β</italic>
</th><th align="left" rowspan="1" colspan="1">SE</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>‐value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MRI outcomes<xref rid="alz13879-tbl6-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">
<italic toggle="yes">n</italic> = 1543</td><td colspan="3" align="left" rowspan="1">
<italic toggle="yes">n</italic> = 483</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">PSMD<xref rid="alz13879-tbl6-note-0005" ref-type="table-fn">
<sup>d</sup>
</xref>, <xref rid="alz13879-tbl6-note-0006" ref-type="table-fn">
<sup>e</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">sOB‐R<xref rid="alz13879-tbl6-note-0005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.04</td><td align="char" rowspan="1" colspan="1">
<bold>0.054</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.023</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.156</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.048</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FLI<xref rid="alz13879-tbl6-note-0005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">−0.059</td><td align="char" rowspan="1" colspan="1">0.031</td><td align="char" rowspan="1" colspan="1">0.06</td><td align="char" rowspan="1" colspan="1">
<bold>−0.188</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.068</bold>
</td><td align="char" rowspan="1" colspan="1">
<bold>0.006</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="alz13879-tbl6-note-0001"><p>
<italic toggle="yes">Note</italic>: Values represent beta coefficients (<italic toggle="yes">β</italic>), and their corresponding standard errors (SE) and <italic toggle="yes">p</italic>‐values (<italic toggle="yes">p</italic>). Statistically significant findings at <italic toggle="yes">p</italic> ≤0.05 are indicated in bold.</p></fn><fn id="alz13879-tbl6-note-0007"><p>Abbreviations: FLI, free leptin index; HVOT, Hooper Visual Organization Test; MRI, magnetic resonance imaging; sOB‐R, soluble leptin receptor; WHR, waist‐to‐hip ratio; WMH, white matter hyperintensity volume.</p></fn><fn id="alz13879-tbl6-note-0002"><label>
<sup>a</sup>
</label><p>Linear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker, WHR, as well as their product term as the main predictors. Values represent the <italic toggle="yes">p</italic>‐value of the respective product term (<italic toggle="yes">p</italic> for interaction). Only significant findings at <italic toggle="yes">p</italic> ≤ 0.1 are presented.</p></fn><fn id="alz13879-tbl6-note-0003"><label>
<sup>b</sup>
</label><p>Linear regression models with the respective MRI measure or neuropsychological test score as the outcome and the respective leptin marker as the main predictor, conducted in different WHR subgroups.</p></fn><fn id="alz13879-tbl6-note-0004"><p>
<sup>c</sup>Models are adjusted for age, sex, diabetes mellitus, body mass index, systolic blood pressure, antihypertensive medication use, current smoking, prevalent cardiovascular disease, and time interval between blood draw and MRI acquisition.</p></fn><fn id="alz13879-tbl6-note-0005"><label>
<sup>d</sup>
</label><p>These variables have been natural log‐transformed to normalize their distributions.</p></fn><fn id="alz13879-tbl6-note-0006"><label>
<sup>e</sup>
</label><p>Models are further adjusted for total cranial volume.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec></sec><sec id="alz13879-sec-0270"><label>4</label><title>DISCUSSION</title><p>In this study, higher leptin bioavailability, indicated by decreased concentrations of its soluble receptor and higher FLI, was associated with better WM integrity in cognitively healthy, community‐dwelling middle‐aged adults. Considering the relatively young age, and good cognitive and cardiovascular health of the FHS participants, these observations may suggest that leptin perturbations are present in individuals with early subclinical neuropathology.</p><sec id="alz13879-sec-0280"><label>4.1</label><title>Leptin markers and cognitive measures</title><p>In AD, neuropathological changes begin many years before the emergence of clinical symptoms.<xref rid="alz13879-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> Similarly, vascular brain damage can exist without evident cognitive impairment, and such asymptomatic individuals are at increased risk for future decline.<xref rid="alz13879-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> During these preclinical disease stages, although neuropathology may already be present, cognitive function remains within the population norms. This likely corresponds to the settings of the present study, considering the inclusion of predominantly young and healthy participants, and might account for the lack of associations between leptin bioavailability and cognitive performance measures. Nevertheless, longitudinal studies are warranted to investigate whether leptin perturbations in cognitively normal individuals increase the risk of future cognitive decline.</p><p>It is also possible that relationships between leptin signaling and cognition are modulated by sex. In stratified analyses, higher leptin bioavailability was associated with better visuospatial skills and executive function in men. These associations were not observed in the total sample but became evident in subgroup analyses despite the lower power, indicating that sex might act as an effect modifier in the relationships between leptin and cognition. In line with this hypothesis, excessive leptin per unit fat was positively associated with cognitive performance in white men but not women in the Dallas Heart Study.<xref rid="alz13879-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p></sec><sec id="alz13879-sec-0290"><label>4.2</label><title>Leptin markers and volumetric brain indices</title><p>Higher plasma leptin concentrations were associated with larger total cerebral brain volume but not with temporal horn volume in a sub‐sample of 198 cognitively healthy participants with a mean age of 79 years from the Original cohort of the FHS.<xref rid="alz13879-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Furthermore, in 527 Dutch participants 70–82 years of age from the Pravastatin in elderly individuals at risk for vascular disease (PROSPER) study, higher serum leptin was associated with higher volume of the amygdala but not with other brain volumes.<xref rid="alz13879-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Conversely, higher plasma leptin was associated with regional brain volume deficits in a set of 517 participants (mean age 75 years) from the Alzheimer's disease neuroimaging initiative (ADNI) study.<xref rid="alz13879-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> The variability surrounding these prior findings might be due to residual confounding introduced by the accumulation of neurodegenerative and cerebrovascular pathologies in older individuals,<xref rid="alz13879-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="alz13879-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="alz13879-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> which might in turn alter leptin signaling pathways.<xref rid="alz13879-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="alz13879-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="alz13879-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> To overcome this issue, along with potential power limitations of prior approaches, we studied the associations of leptin markers with volumetric brain indices in a relatively large sample of cognitively healthy middle‐aged adults with &lt; 1% prevalence of CVD. Additionally, taking into account that the development of central leptin resistance might lead to a state of relative leptin deficiency despite apparently high concentrations of circulating leptin,<xref rid="alz13879-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> we included leptin bioavailability in our analysis, considering it might better reflect underlying leptin signaling states. Nevertheless, no associations of leptin markers with total brain, cortical gray matter, or hippocampal volumes were observed in the younger FHS sample. This might be related to the relatively young age (brain volume changes usually appear later in life<xref rid="alz13879-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>) and overall good cognitive and cardiovascular health of study participants, leading to an overall preserved brain morphology.</p></sec><sec id="alz13879-sec-0300"><label>4.3</label><title>Leptin markers and white matter microstructural integrity</title><p>The “disconnected brain” hypothesis posits that aging‐accompanying cognitive changes are the consequence of disrupted communication between different (mainly distant) cortical regions since higher‐order cognitive functions rely on the speed and efficiency of communication among large‐scale neural networks.<xref rid="alz13879-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="alz13879-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> WM integrity seems to mediate this relationship between age and cognition through cortical disconnection<xref rid="alz13879-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>; therefore, WM integrity alterations might explain potential deviations from the normal aging pattern that lead to the development of dementia. This is evidenced by the loss of WM integrity in AD, starting in the prodromal stages,<xref rid="alz13879-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref> and in individuals with VCID, during both the symptomatic<xref rid="alz13879-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> and pre‐symptomatic<xref rid="alz13879-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> period. Consequently, alterations in WM integrity likely represent an early subclinical process in those at risk for cognitive impairment due to AD and/or vascular pathology, entities collectively accounting for the vast majority of dementia cases worldwide.<xref rid="alz13879-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> WM integrity can be evaluated using DTI‐derived measures, with FA (expressing the degree to which a single diffusion orientation is dominant) and MD (expressing the average amount of apparent diffusion along each of the three diffusion axes) being among the most commonly used ones; higher FA and lower MD indicate higher tissue integrity.<xref rid="alz13879-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> A more recent diffusion metric is the FW index, which measures the fraction of the diffusion signal explained by isotropically unrestricted water.<xref rid="alz13879-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> FW has been proposed as a sensitive biomarker of cognitive function and of subtle brain injury related to vascular risk factors.<xref rid="alz13879-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="alz13879-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> It might also aid in the differentiation between healthy individuals and those with AD or MCI.<xref rid="alz13879-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> Although the precise biological mechanisms linking increases in WM FW signal to AD or vascular pathology remain unclear, these could, for example, involve WM inflammation in the setting of AD,<xref rid="alz13879-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> or vasogenic edema and intramyelinic vacuolization in the setting of small vessel disease.<xref rid="alz13879-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</p><p>Herein, we report associations of leptin bioavailability with all markers of WM integrity considered in the present analysis. These findings support the putative neuroprotective role of leptin,<xref rid="alz13879-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="alz13879-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>, <xref rid="alz13879-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> and might account for its previously reported associations with lower dementia risk.<xref rid="alz13879-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Specifically, the link of higher leptin bioavailability during midlife with better preservation of WM microstructure suggests a potential for better maintenance of cognitive functions and, consequently, lower dementia risk later in life by virtue of more efficient connectivity. Of note, the effect sizes of the associations between leptin bioavailability and PSMD were larger in participants with excess WHR, indicating that potential benefits might be even higher for individuals with visceral obesity.</p><p>Importantly, we replicated the association of increased leptin receptor concentrations with higher PSMD in an independent sample of dementia‐free Mexican American older adults, expanding the generalizability and external validity of our findings. Associations with other DTI measures were not significant in our replication sample, likely due to the considerably smaller size (<italic toggle="yes">n</italic> = 89), limiting the power to detect associations compared to FHS. Nevertheless, these findings highlight the sensitivity of PSMD to capture associations between measures of interest and WM microstructural changes, even in small samples. This might be related to a variety of reasons. First, MD is one of the most robust metrics with respect to underlying WM tissue characteristics.<xref rid="alz13879-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> In contrast, FA has been criticized for its dependency on fiber geometry. Specifically, higher FA values might not necessarily reflect better tissue integrity (e.g., higher fiber density, lower membrane permeability, greater myelination, etc.), due to the presence of crossing fibers throughout the majority of cerebral WM.<xref rid="alz13879-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Notably, PSMD performs even better than traditional MD by leveraging skeletonization to focus the analysis of MD on the main fiber tracts, eliminating CSF contamination.<xref rid="alz13879-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Perhaps even more importantly for replication purposes, the peak width is calculated as the difference between the 95th and 5th percentiles of the voxel‐based MD values within the skeleton and does not depend on absolute MD values, rendering PSMD less prone to inter‐scanner and inter‐study differences than other DTI parameters.<xref rid="alz13879-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p></sec><sec id="alz13879-sec-0310"><label>4.4</label><title>Leptin markers and subclinical neuropathology</title><p>Identifying associations with risk factors and health outcomes of interest during the preclinical dementia stages is challenging due to often normal cognitive measures. Biomarkers of amyloid‐β and tau pathology <xref rid="alz13879-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="alz13879-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="alz13879-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> offer valuable alternatives for studying such associations during the preclinical stages of AD. However, for VCID such well‐characterized biomarkers were, until recently, lacking.<xref rid="alz13879-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Prior investigations have demonstrated that alterations in WM microstructure precede the development of cognitive decline in individuals who will later develop cognitive impairment due to either AD‐driven<xref rid="alz13879-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="alz13879-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="alz13879-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> or vascular pathology,<xref rid="alz13879-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>, <xref rid="alz13879-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> highlighting their potential utility as susceptibility/risk biomarkers in these settings.<xref rid="alz13879-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> Capitalizing on these prior insights, we leveraged DTI‐derived measures as sensitive surrogate markers of subclinical neuropathology in two independent samples of dementia‐free individuals to study and identify associations with leptin bioavailability.</p></sec><sec id="alz13879-sec-0320"><label>4.5</label><title>Limitations</title><p>The mean delay of 8 years between exposure (leptin markers) and outcome (MRI and cognitive measures) assessment might have introduced noise to our data and led to false negative findings. Nevertheless, the detection of associations between leptin bioavailability and WM microstructural integrity despite a potentially increased noise‐to‐signal ratio, suggests that the underlying relationships might in fact be even stronger. We also replicated the association of higher leptin receptor concentration with worse WM microstructural integrity, as assessed with PSMD, in an older sample of different ethnicity with synchronous exposure and outcome assessments. Nevertheless, the cross‐sectional design of the present analysis does not allow for causal or temporal inferences. Longitudinal studies are needed to examine associations of leptin bioavailability in middle age with the risk for dementia or cognitive decline later in life. Studies exploring associations with biomarkers of amyloid‐β and/or tau pathology would also be important to elucidate whether lower leptin bioavailability is associated with the presence of core AD neuropathology in cognitively intact middle‐aged adults.</p></sec></sec><sec id="alz13879-sec-0330"><label>5</label><title>CONCLUSION</title><p>In summary, the present findings support the putative role of leptin perturbations in late‐life dementia risk by relating relative leptin deficiency (i.e., lower leptin bioavailability) with alterations in WM microstructure, an early event in the pathogenetic processes of cognitive impairment due to AD‐driven and/or vascular pathology.</p></sec><sec sec-type="COI-statement" id="alz13879-sec-0350"><title>CONFLICT OF INTEREST STATEMENT</title><p>Dr. DeCarli reports consulting for Novartis Pharmaceuticals. Dr. Seshadri reports consulting for Eisai and Biogen. The rest of the authors have nothing to disclose. Author disclosures are available in the <xref rid="alz13879-supitem-0002" ref-type="supplementary-material">supporting information</xref>.</p></sec><sec id="alz13879-sec-0360"><title>CONSENT STATEMENT</title><p>All study participants have provided written informed consent.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="alz13879-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-20-5849-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="alz13879-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ALZ-20-5849-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="alz13879-sec-0340"><title>ACKNOWLEDGMENTS</title><p>We thank the FHS and MarkVCID‐1 study participants as well as the study team for their contributions to data collection, without which the present work would not be feasible. Data used in preparation of this article were obtained from the MarkVCID consortium. A complete listing of MarkVCID investigators can be found on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.markvcid.org" ext-link-type="uri">www.markvcid.org</ext-link>. This work was funded by the National Heart Lung and Blood Institute (Framingham Heart Study Contracts No. N01‐HC‐25195, No. HHSN268201500001I, and No. 75N92019D00031), Boston University School of Medicine, and grants from the National Institute on Aging (NIA; R01 AG054076, R01 AG049607, U01 AG052409, R01 AG059421, RF1 AG063507, RF1 AG066524, U01 AG058589), the National Institute of Neurological Disorders and Stroke (NINDS; R01 NS017950, UH2 NS100605, UF1/UH1 NS125513), and the National Institute of Diabetes and Digestive and Kidney (R01 DK080739).</p><p>Data collection and sharing for this project was funded by NINDS/NIA as part of the MarkVCID Consortium (U24NS100591). Data used in the preparation of this article were obtained from the (NIH) Biomarkers Consortium for Vascular Contributions to Cognitive Impairment and Dementia (MarkVCID) database. MarkVCID was launched in 2016 by the NIH's NINDS and NIA, and consists of research groups across the United States. The primary goal of MarkVCID is to generate a suite of validated biomarkers ready for application to clinical trials aimed at identifying disease‐modifying therapies for VCID. For up‐to‐date information, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.markvcid.org" ext-link-type="uri">www.markvcid.org</ext-link>.</p><p>Dr. Satizabal was supported by a New Investigator Research Grant to promote Diversity from the Alzheimer's Association (AARGD‐16‐443384) and also receives support from NIA (R01 AG059727 and R01 AG082360). Drs. Satizabal, Himali, and Seshadri are partially supported by the South Texas Alzheimer's Disease Research Center (P30 AG066546). Drs. Seshadri and Himali receive support from The Bill and Rebecca Reed Endowment for Precision Therapies and Palliative Care. Dr. Himali is supported by an endowment from the William Castella family as William Castella Distinguished University Chair for Alzheimer's Disease Research, and Dr. Seshadri by an endowment from the Barker Foundation as the Robert R Barker Distinguished University Professor of Neurology, Psychiatry and Cellular and Integrative Physiology. Dr. DeCarli received funding from P30 AG0101029 and P30 AG072972. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></ack><ref-list id="alz13879-bibl-0001"><title>REFERENCES</title><ref id="alz13879-bib-0001"><label>1</label><mixed-citation publication-type="book" id="alz13879-cit-0001"><string-name name-style="western"><surname>Comas Herrera</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Prince</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Knapp</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Karagiannidou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Guerchet</surname><given-names>M</given-names></string-name>, <article-title>World Alzheimer Report 2016: Improving healthcare for people with dementia. coverage, quality and costs now and in the future</article-title>. <publisher-name>Alzheimer's Disease International</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="alz13879-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="alz13879-cit-0002"><string-name name-style="western"><surname>Nianogo</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Rosenwohl‐Mack</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yaffe</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Carrasco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Barnes</surname><given-names>DE</given-names></string-name>. <article-title>Risk Factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US</article-title>. <source>JAMA Neurol</source>. <year>2022</year>;<volume>79</volume>(<issue>6</issue>):<fpage>584</fpage>‐<lpage>591</lpage>.<pub-id pub-id-type="pmid">35532912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2022.0976</pub-id><pub-id pub-id-type="pmcid">PMC9086930</pub-id></mixed-citation></ref><ref id="alz13879-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="alz13879-cit-0003"><string-name name-style="western"><surname>Kivipelto</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ngandu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Fratiglioni</surname><given-names>L</given-names></string-name>, et al. <article-title>Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>2005</year>;<volume>62</volume>(<issue>10</issue>):<fpage>1556</fpage>‐<lpage>1560</lpage>.<pub-id pub-id-type="pmid">16216938</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.62.10.1556</pub-id></mixed-citation></ref><ref id="alz13879-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="alz13879-cit-0004"><string-name name-style="western"><surname>Charisis</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ray</surname><given-names>R</given-names></string-name>, et al. <article-title>Obesity impacts the expression of Alzheimer's disease‐related genes: the Framingham Heart Study</article-title>. <source>Alzheimers Dement</source>. <year>2023</year>;<volume>19</volume>(<issue>8</issue>):<fpage>3496</fpage>‐<lpage>3505</lpage>.<pub-id pub-id-type="pmid">36811231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12954</pub-id><pub-id pub-id-type="pmcid">PMC10435662</pub-id></mixed-citation></ref><ref id="alz13879-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="alz13879-cit-0005"><string-name name-style="western"><surname>Tabassum</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Misrani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>L</given-names></string-name>. <article-title>Exploiting common aspects of obesity and Alzheimer's disease</article-title>. <source>Front Hum Neurosci</source>. <year>2020</year>;<volume>14</volume>:<elocation-id>602360</elocation-id>.<pub-id pub-id-type="pmid">33384592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnhum.2020.602360</pub-id><pub-id pub-id-type="pmcid">PMC7769820</pub-id></mixed-citation></ref><ref id="alz13879-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="alz13879-cit-0006"><string-name name-style="western"><surname>Ahima</surname><given-names>RS</given-names></string-name>. <article-title>Adipose tissue as an endocrine organ</article-title>. <source>Obesity</source>. <year>2006</year>;<volume>14</volume>(<issue>5</issue>):<fpage>242S</fpage>‐<lpage>249S</lpage>.<pub-id pub-id-type="pmid">17021375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/oby.2006.317</pub-id></mixed-citation></ref><ref id="alz13879-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="alz13879-cit-0007"><string-name name-style="western"><surname>Forny‐Germano</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>De Felice</surname><given-names>FG</given-names></string-name>, <string-name name-style="western"><surname>Vieira</surname><given-names>MNDN</given-names></string-name>. <article-title>The role of leptin and adiponectin in obesity‐associated cognitive decline and Alzheimer's disease</article-title>. <source>Front Neurosci</source>. <year>2018</year>;<volume>12</volume>:<fpage>1027</fpage>.<pub-id pub-id-type="pmid">30692905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2018.01027</pub-id><pub-id pub-id-type="pmcid">PMC6340072</pub-id></mixed-citation></ref><ref id="alz13879-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="alz13879-cit-0008"><string-name name-style="western"><surname>Lieb</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Beiser</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Vasan</surname><given-names>RS</given-names></string-name>, et al. <article-title>Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>(<issue>23</issue>):<fpage>2565</fpage>‐<lpage>2572</lpage>.<pub-id pub-id-type="pmid">20009056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2009.1836</pub-id><pub-id pub-id-type="pmcid">PMC2838501</pub-id></mixed-citation></ref><ref id="alz13879-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="alz13879-cit-0009"><string-name name-style="western"><surname>Zeki Al Hazzouri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stone</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Haan</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Yaffe</surname><given-names>K</given-names></string-name>. <article-title>Leptin, mild cognitive impairment, and dementia among elderly women</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2013</year>;<volume>68</volume>(<issue>2</issue>):<fpage>175</fpage>‐<lpage>180</lpage>.<pub-id pub-id-type="pmid">22859388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/gls155</pub-id><pub-id pub-id-type="pmcid">PMC3598359</pub-id></mixed-citation></ref><ref id="alz13879-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="alz13879-cit-0010"><string-name name-style="western"><surname>Gustafson</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Bäckman</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lissner</surname><given-names>L</given-names></string-name>, et al. <article-title>Leptin and dementia over 32 years‐The Prospective Population Study of Women</article-title>. <source>Alzheimers Dement</source>. <year>2012</year>;<volume>8</volume>(<issue>4</issue>):<fpage>272</fpage>‐<lpage>277</lpage>.<pub-id pub-id-type="pmid">22748937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2011.05.2411</pub-id></mixed-citation></ref><ref id="alz13879-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="alz13879-cit-0011"><string-name name-style="western"><surname>Sanborn</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Preis</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Ang</surname><given-names>A</given-names></string-name>, et al. <article-title>Association between leptin, cognition, and structural brain measures among “early” middle‐aged adults: results from the Framingham Heart Study Third Generation Cohort</article-title>. <source>J Alzheimers Dis</source>. <year>2020</year>;<volume>77</volume>(<issue>3</issue>):<fpage>1279</fpage>‐<lpage>1289</lpage>.<pub-id pub-id-type="pmid">32831199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/JAD-191247</pub-id><pub-id pub-id-type="pmcid">PMC7923949</pub-id></mixed-citation></ref><ref id="alz13879-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="alz13879-cit-0012"><string-name name-style="western"><surname>Dubois</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hampel</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>HH</given-names></string-name>, et al. <article-title>Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria</article-title>. <source>Alzheimers Dement</source>. <year>2016</year>;<volume>12</volume>(<issue>3</issue>):<fpage>292</fpage>‐<lpage>323</lpage>.<pub-id pub-id-type="pmid">27012484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2016.02.002</pub-id><pub-id pub-id-type="pmcid">PMC6417794</pub-id></mixed-citation></ref><ref id="alz13879-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="alz13879-cit-0013"><string-name name-style="western"><surname>McGuire</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Ishii</surname><given-names>M</given-names></string-name>. <article-title>Leptin dysfunction and Alzheimer's disease: evidence from cellular, animal, and human studies</article-title>. <source>Cell Mol Neurobiol</source>. <year>2016</year>;<volume>36</volume>(<issue>2</issue>):<fpage>203</fpage>‐<lpage>217</lpage>.<pub-id pub-id-type="pmid">26993509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10571-015-0282-7</pub-id><pub-id pub-id-type="pmcid">PMC4846558</pub-id></mixed-citation></ref><ref id="alz13879-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="alz13879-cit-0014"><string-name name-style="western"><surname>Kratzsch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lammert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bottner</surname><given-names>A</given-names></string-name>, et al. <article-title>Circulating soluble leptin receptor and free leptin index during childhood, puberty, and adolescence</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>(<issue>10</issue>):<fpage>4587</fpage>‐<lpage>4594</lpage>.<pub-id pub-id-type="pmid">12364439</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2002-020001</pub-id></mixed-citation></ref><ref id="alz13879-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="alz13879-cit-0015"><string-name name-style="western"><surname>Herrick</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Panza</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Gollie</surname><given-names>JM</given-names></string-name>. <article-title>Leptin, leptin soluble receptor, and the free leptin index following a diet and physical activity lifestyle intervention in obese males and females</article-title>. <source>J Obes</source>. <year>2016</year>;<volume>2016</volume>:<elocation-id>8375828</elocation-id>.<pub-id pub-id-type="pmid">28050279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2016/8375828</pub-id><pub-id pub-id-type="pmcid">PMC5168550</pub-id></mixed-citation></ref><ref id="alz13879-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="alz13879-cit-0016"><string-name name-style="western"><surname>Albala</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Angel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lera</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Marquez</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fuentes</surname><given-names>P</given-names></string-name>. <article-title>Low leptin availability as a risk factor for dementia in Chilean older people</article-title>. <source>Dement Geriatr Cogn Dis Extra</source>. <year>2016</year>;<volume>6</volume>(<issue>2</issue>):<fpage>295</fpage>‐<lpage>302</lpage>.<pub-id pub-id-type="pmid">27504118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000447447</pub-id><pub-id pub-id-type="pmcid">PMC4965539</pub-id></mixed-citation></ref><ref id="alz13879-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="alz13879-cit-0017"><string-name name-style="western"><surname>Splansky</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Corey</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, et al. <article-title>The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination</article-title>. <source>Am J Epidemiol</source>. <year>2007</year>;<volume>165</volume>(<issue>11</issue>):<fpage>1328</fpage>‐<lpage>1335</lpage>.<pub-id pub-id-type="pmid">17372189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwm021</pub-id></mixed-citation></ref><ref id="alz13879-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="alz13879-cit-0018"><string-name name-style="western"><surname>Zachariah</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hamburg</surname><given-names>NM</given-names></string-name>, et al. <article-title>Circulating Adipokines and vascular function: cross‐sectional associations in a community‐based cohort</article-title>. <source>Hypertension</source>. <year>2016</year>;<volume>67</volume>(<issue>2</issue>):<fpage>294</fpage>‐<lpage>300</lpage>.<pub-id pub-id-type="pmid">26628673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.115.05949</pub-id><pub-id pub-id-type="pmcid">PMC4845672</pub-id></mixed-citation></ref><ref id="alz13879-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="alz13879-cit-0019"><string-name name-style="western"><surname>McGrath</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Himali</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>D</given-names></string-name>, et al. <article-title>Circulating IGFBP‐2: a novel biomarker for incident dementia</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2019</year>;<volume>6</volume>(<issue>9</issue>):<fpage>1659</fpage>‐<lpage>1670</lpage>.<pub-id pub-id-type="pmid">31373442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acn3.50854</pub-id><pub-id pub-id-type="pmcid">PMC6764739</pub-id></mixed-citation></ref><ref id="alz13879-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="alz13879-cit-0020"><string-name name-style="western"><surname>Fletcher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>DeCarli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Knaack</surname><given-names>A</given-names></string-name>. <article-title>Convolutional neural net learning can achieve production‐level brain segmentation in structural magnetic resonance imaging</article-title>. <source>Front Neurosci.</source><year>2021</year>;<volume>15</volume>:<elocation-id>683426</elocation-id>.<pub-id pub-id-type="pmid">34234642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.683426</pub-id><pub-id pub-id-type="pmcid">PMC8255694</pub-id></mixed-citation></ref><ref id="alz13879-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="alz13879-cit-0021"><string-name name-style="western"><surname>Pasternak</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Sochen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gur</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Intrator</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Assaf</surname><given-names>Y</given-names></string-name>. <article-title>Free water elimination and mapping from Diffusion MRI</article-title>. <source>Magn Reson Med</source>. <year>2009</year>;<volume>62</volume>(<issue>3</issue>):<fpage>717</fpage>‐<lpage>730</lpage>.<pub-id pub-id-type="pmid">19623619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mrm.22055</pub-id></mixed-citation></ref><ref id="alz13879-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="alz13879-cit-0022"><string-name name-style="western"><surname>Baykara</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gesierich</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Adam</surname><given-names>R</given-names></string-name>, et al. <article-title>A novel imaging marker for small vessel disease based on skeletonization of white matter tracts and diffusion histograms</article-title>. <source>Ann Neurol</source>. <year>2016</year>;<volume>80</volume>(<issue>4</issue>):<fpage>581</fpage>‐<lpage>592</lpage>.<pub-id pub-id-type="pmid">27518166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24758</pub-id></mixed-citation></ref><ref id="alz13879-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="alz13879-cit-0023"><string-name name-style="western"><surname>Maillard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></string-name>, et al. <article-title>Instrumental validation of free water, peak‐width of skeletonized mean diffusivity, and white matter hyperintensities: markVCID neuroimaging kits</article-title>. <source>Alzheimers Dement</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<elocation-id>e12261</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dad2.12261</pub-id><pub-id pub-id-type="pmcid">PMC8959640</pub-id><pub-id pub-id-type="pmid">35382232</pub-id></mixed-citation></ref><ref id="alz13879-bib-0024"><label>24</label><mixed-citation publication-type="book" id="alz13879-cit-0024"><string-name name-style="western"><surname>Smith</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Kindlmann</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jbabdi</surname><given-names>S</given-names></string-name>. <part-title>Chapter 10 ‐ Cross‐Subject Comparison of Local DiffusionMRI Parameters</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Johansen‐Berg</surname><given-names>H</given-names></string-name></person-group>, <person-group person-group-type="editor"><string-name name-style="western"><surname>Behrens</surname><given-names>TEJ</given-names></string-name></person-group>, eds. <source>Diffusion MRI (Second Edition)</source>. <publisher-name>Academic Press</publisher-name>; <year>2014</year>:<fpage>209</fpage>‐<lpage>239</lpage>.</mixed-citation></ref><ref id="alz13879-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="alz13879-cit-0025"><article-title>PSMD (Peak width of Skeletonized Mean Diffusivity)</article-title>. Accessed February 28, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.psmd-marker.com" ext-link-type="uri">http://www.psmd‐marker.com</ext-link></mixed-citation></ref><ref id="alz13879-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="alz13879-cit-0026"><string-name name-style="western"><surname>Metzler‐Baddeley</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>O'Sullivan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Bells</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pasternak</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DK</given-names></string-name>. <article-title>How and how not to correct for CSF‐contamination in Diffusion MRI</article-title>. <source>Neuroimage</source>. <year>2012</year>;<volume>59</volume>(<issue>2</issue>):<fpage>1394</fpage>‐<lpage>1403</lpage>.<pub-id pub-id-type="pmid">21924365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.08.043</pub-id></mixed-citation></ref><ref id="alz13879-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="alz13879-cit-0027"><string-name name-style="western"><surname>Ingelsson</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Larson</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>X</given-names></string-name>, et al. <article-title>Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community‐based sample</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>(<issue>8</issue>):<fpage>3149</fpage>‐<lpage>3157</lpage>.<pub-id pub-id-type="pmid">18492761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-0207</pub-id><pub-id pub-id-type="pmcid">PMC2515078</pub-id></mixed-citation></ref><ref id="alz13879-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="alz13879-cit-0028"><string-name name-style="western"><surname>Takao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Inano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ohtomo</surname><given-names>K</given-names></string-name>. <article-title>Effect of head size on diffusion tensor imaging</article-title>. <source>Neuroimage</source>. <year>2011</year>;<volume>57</volume>(<issue>3</issue>):<fpage>958</fpage>‐<lpage>967</lpage>.<pub-id pub-id-type="pmid">21605689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroimage.2011.05.019</pub-id></mixed-citation></ref><ref id="alz13879-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="alz13879-cit-0029"><string-name name-style="western"><surname>Benjamini</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hochberg</surname><given-names>Y</given-names></string-name>. <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source>J R Stat</source>. <year>1995</year>;<volume>57</volume>(<issue>1</issue>):<fpage>289</fpage>‐<lpage>300</lpage>.</mixed-citation></ref><ref id="alz13879-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="alz13879-cit-0030"><string-name name-style="western"><surname>Wilcock</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Jicha</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Blacker</surname><given-names>D</given-names></string-name>, et al. <article-title>MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>4</issue>):<fpage>704</fpage>‐<lpage>715</lpage>.<pub-id pub-id-type="pmid">33480172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12215</pub-id><pub-id pub-id-type="pmcid">PMC8122220</pub-id></mixed-citation></ref><ref id="alz13879-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="alz13879-cit-0031"><string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kashani</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Arfanakis</surname><given-names>K</given-names></string-name>, et al. <article-title>MarkVCID cerebral small vessel consortium: II. neuroimaging protocols</article-title>. <source>Alzheimers Dement</source>. <year>2021</year>;<volume>17</volume>(<issue>4</issue>):<fpage>716</fpage>‐<lpage>725</lpage>.<pub-id pub-id-type="pmid">33480157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/alz.12216</pub-id><pub-id pub-id-type="pmcid">PMC8627001</pub-id></mixed-citation></ref><ref id="alz13879-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="alz13879-cit-0032"><string-name name-style="western"><surname>Craft</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Newcomer</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kanne</surname><given-names>S</given-names></string-name>, et al. <article-title>Memory improvement following induced hyperinsulinemia in Alzheimer's disease</article-title>. <source>Neurobiol Aging</source>. <year>1996</year>;<volume>17</volume>(<issue>1</issue>):<fpage>123</fpage>‐<lpage>130</lpage>.<pub-id pub-id-type="pmid">8786794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0197-4580(95)02002-0</pub-id></mixed-citation></ref><ref id="alz13879-bib-0033"><label>33</label><mixed-citation publication-type="book" id="alz13879-cit-0033"><string-name name-style="western"><surname>Brownson</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Petitti</surname><given-names>DB</given-names></string-name>. <source>Applied Epidemiology: Theory To Practice</source>. <edition>2nd ed.</edition>. <publisher-name>Oxford University Press</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="alz13879-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="alz13879-cit-0034"><string-name name-style="western"><surname>Sachdev</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Kalaria</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>O'Brien</surname><given-names>J</given-names></string-name>, et al. <article-title>Diagnostic criteria for vascular cognitive disorders: a VASCOG statement</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2014</year>;<volume>28</volume>(<issue>3</issue>):<fpage>206</fpage>‐<lpage>218</lpage>.<pub-id pub-id-type="pmid">24632990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WAD.0000000000000034</pub-id><pub-id pub-id-type="pmcid">PMC4139434</pub-id></mixed-citation></ref><ref id="alz13879-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="alz13879-cit-0035"><string-name name-style="western"><surname>Warren</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Hynan</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>MF</given-names></string-name>. <article-title>Leptin and cognition</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2012</year>;<volume>33</volume>(<issue>6</issue>):<fpage>410</fpage>‐<lpage>415</lpage>.<pub-id pub-id-type="pmid">22814193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000339956</pub-id><pub-id pub-id-type="pmcid">PMC3732374</pub-id></mixed-citation></ref><ref id="alz13879-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="alz13879-cit-0036"><string-name name-style="western"><surname>Zonneveld</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Noordam</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>van der Grond</surname><given-names>J</given-names></string-name>, et al. <article-title>Interplay of circulating leptin and obesity in cognition and cerebral volumes in older adults</article-title>. <source>Peptides</source>. <year>2021</year>;<volume>135</volume>:<elocation-id>170424</elocation-id>.<pub-id pub-id-type="pmid">33058961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.peptides.2020.170424</pub-id></mixed-citation></ref><ref id="alz13879-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="alz13879-cit-0037"><string-name name-style="western"><surname>Rajagopalan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Toga</surname><given-names>AW</given-names></string-name>, <string-name name-style="western"><surname>Jack</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>PM</given-names></string-name>. <article-title>Alzheimer's disease Neuroimaging I. Fat‐mass‐related hormone, plasma leptin, predicts brain volumes in the elderly</article-title>. <source>Neuroreport</source>. <year>2013</year>;<volume>24</volume>(<issue>2</issue>):<fpage>58</fpage>‐<lpage>62</lpage>.<pub-id pub-id-type="pmid">23238164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WNR.0b013e32835c5254</pub-id><pub-id pub-id-type="pmcid">PMC3635486</pub-id></mixed-citation></ref><ref id="alz13879-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="alz13879-cit-0038"><string-name name-style="western"><surname>DeCarli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Massaro</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Harvey</surname><given-names>D</given-names></string-name>, et al. <article-title>Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal</article-title>. <source>Neurobiol Aging</source>. <year>2005</year>;<volume>26</volume>(<issue>4</issue>):<fpage>491</fpage>‐<lpage>510</lpage>.<pub-id pub-id-type="pmid">15653178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2004.05.004</pub-id></mixed-citation></ref><ref id="alz13879-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="alz13879-cit-0039"><string-name name-style="western"><surname>Jansen</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Ossenkoppele</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Knol</surname><given-names>DL</given-names></string-name>, et al. <article-title>Prevalence of cerebral amyloid pathology in persons without dementia: a meta‐analysis</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>313</volume>(<issue>19</issue>):<fpage>1924</fpage>‐<lpage>1938</lpage>.<pub-id pub-id-type="pmid">25988462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2015.4668</pub-id><pub-id pub-id-type="pmcid">PMC4486209</pub-id></mixed-citation></ref><ref id="alz13879-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="alz13879-cit-0040"><string-name name-style="western"><surname>Legdeur</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tijms</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Konijnenberg</surname><given-names>E</given-names></string-name>, et al. <article-title>Associations of brain pathology cognitive and physical markers with age in cognitively normal individuals aged 60‐102 years</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2020</year>;<volume>75</volume>(<issue>9</issue>):<fpage>1609</fpage>‐<lpage>1617</lpage>.<pub-id pub-id-type="pmid">31411322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glz180</pub-id><pub-id pub-id-type="pmcid">PMC7494041</pub-id></mixed-citation></ref><ref id="alz13879-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="alz13879-cit-0041"><string-name name-style="western"><surname>Cecon</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lhomme</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Maurice</surname><given-names>T</given-names></string-name>, et al. <article-title>Amyloid beta peptide is an endogenous negative allosteric modulator of leptin receptor</article-title>. <source>Neuroendocrinology</source>. <year>2021</year>;<volume>111</volume>(<issue>4</issue>):<fpage>370</fpage>‐<lpage>387</lpage>.<pub-id pub-id-type="pmid">32335558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000508105</pub-id></mixed-citation></ref><ref id="alz13879-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="alz13879-cit-0042"><string-name name-style="western"><surname>King</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hanson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Dittmann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Vickers</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fernandez‐Martos</surname><given-names>C</given-names></string-name>. <article-title>Disruption of leptin signalling in a mouse model of Alzheimer's disease</article-title>. <source>Metab Brain Dis</source>. <year>2018</year>;<volume>33</volume>(<issue>4</issue>):<fpage>1097</fpage>‐<lpage>1110</lpage>.<pub-id pub-id-type="pmid">29546689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11011-018-0203-9</pub-id></mixed-citation></ref><ref id="alz13879-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="alz13879-cit-0043"><string-name name-style="western"><surname>Bonda</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Stone</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>SL</given-names></string-name>, et al. <article-title>Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance</article-title>. <source>J Neurochem</source>. <year>2014</year>;<volume>128</volume>(<issue>1</issue>):<fpage>162</fpage>‐<lpage>172</lpage>.<pub-id pub-id-type="pmid">23895348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jnc.12380</pub-id><pub-id pub-id-type="pmcid">PMC3867585</pub-id></mixed-citation></ref><ref id="alz13879-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="alz13879-cit-0044"><string-name name-style="western"><surname>Raz</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lindenberger</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Rodrigue</surname><given-names>KM</given-names></string-name>, et al. <article-title>Regional brain changes in aging healthy adults: general trends, individual differences and modifiers</article-title>. <source>Cerebral Cortex</source>. <year>2005</year>;<volume>15</volume>(<issue>11</issue>):<fpage>1676</fpage>‐<lpage>1689</lpage>.<pub-id pub-id-type="pmid">15703252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cercor/bhi044</pub-id></mixed-citation></ref><ref id="alz13879-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="alz13879-cit-0045"><string-name name-style="western"><surname>Madden</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Parks</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Tallman</surname><given-names>CW</given-names></string-name>, et al. <article-title>Sources of disconnection in neurocognitive aging: cerebral white‐matter integrity, resting‐state functional connectivity, and white‐matter hyperintensity volume</article-title>. <source>Neurobiol Aging</source>. <year>2017</year>;<volume>54</volume>:<fpage>199</fpage>‐<lpage>213</lpage>.<pub-id pub-id-type="pmid">28389085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2017.01.027</pub-id><pub-id pub-id-type="pmcid">PMC5401777</pub-id></mixed-citation></ref><ref id="alz13879-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="alz13879-cit-0046"><string-name name-style="western"><surname>Bennett</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Madden</surname><given-names>DJ</given-names></string-name>. <article-title>Disconnected aging: cerebral white matter integrity and age‐related differences in cognition</article-title>. <source>Neuroscience</source>. <year>2014</year>;<volume>276</volume>:<fpage>187</fpage>‐<lpage>205</lpage>.<pub-id pub-id-type="pmid">24280637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuroscience.2013.11.026</pub-id><pub-id pub-id-type="pmcid">PMC4032380</pub-id></mixed-citation></ref><ref id="alz13879-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="alz13879-cit-0047"><string-name name-style="western"><surname>Kantarci</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schwarz</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Reid</surname><given-names>RI</given-names></string-name>, et al. <article-title>White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration</article-title>. <source>JAMA Neurol</source>. <year>2014</year>;<volume>71</volume>(<issue>12</issue>):<fpage>1547</fpage>‐<lpage>1554</lpage>.<pub-id pub-id-type="pmid">25347157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2014.1482</pub-id><pub-id pub-id-type="pmcid">PMC4810441</pub-id></mixed-citation></ref><ref id="alz13879-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="alz13879-cit-0048"><string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>RG</given-names></string-name>, et al. <article-title>Mechanisms of cognitive impairment in cerebral small vessel disease: multimodal MRI results from the St George's cognition and neuroimaging in stroke (SCANS) study</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<elocation-id>e61014</elocation-id>.<pub-id pub-id-type="pmid">23613774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0061014</pub-id><pub-id pub-id-type="pmcid">PMC3632543</pub-id></mixed-citation></ref><ref id="alz13879-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="alz13879-cit-0049"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, et al. <article-title>Alterations of white matter integrity in subcortical ischemic vascular disease with and without cognitive impairment: a TBSS Study</article-title>. <source>J Mol Neurosci</source>. <year>2019</year>;<volume>67</volume>(<issue>4</issue>):<fpage>595</fpage>‐<lpage>603</lpage>.<pub-id pub-id-type="pmid">30685818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12031-019-01266-3</pub-id></mixed-citation></ref><ref id="alz13879-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="alz13879-cit-0050"><string-name name-style="western"><surname>Rizzi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rosset</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Roriz‐Cruz</surname><given-names>M</given-names></string-name>. <article-title>Global epidemiology of dementia: Alzheimer's and vascular types</article-title>. <source>Biomed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<elocation-id>908915</elocation-id>.<pub-id pub-id-type="pmid">25089278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/908915</pub-id><pub-id pub-id-type="pmcid">PMC4095986</pub-id></mixed-citation></ref><ref id="alz13879-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="alz13879-cit-0051"><string-name name-style="western"><surname>Maillard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fletcher</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>B</given-names></string-name>, et al. <article-title>Cerebral white matter free water: a sensitive biomarker of cognition and function</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>(<issue>19</issue>):<fpage>e2221</fpage>‐<lpage>e2231</lpage>.<pub-id pub-id-type="pmid">30952798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000007449</pub-id><pub-id pub-id-type="pmcid">PMC6537135</pub-id></mixed-citation></ref><ref id="alz13879-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="alz13879-cit-0052"><string-name name-style="western"><surname>Maillard</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Himali</surname><given-names>JJ</given-names></string-name>, et al. <article-title>Aortic stiffness, increased white matter free water, and altered microstructural integrity: a continuum of injury</article-title>. <source>Stroke</source>. <year>2017</year>;<volume>48</volume>(<issue>6</issue>):<fpage>1567</fpage>‐<lpage>1573</lpage>.<pub-id pub-id-type="pmid">28473633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.116.016321</pub-id><pub-id pub-id-type="pmcid">PMC5502744</pub-id></mixed-citation></ref><ref id="alz13879-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="alz13879-cit-0053"><string-name name-style="western"><surname>Dumont</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jodoin</surname><given-names>PM</given-names></string-name>, et al. <article-title>Free water in white matter differentiates MCI and AD from control subjects</article-title>. <source>Front Aging Neurosci</source>. <year>2019</year>;<volume>11</volume>:<fpage>270</fpage>.<pub-id pub-id-type="pmid">31632265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2019.00270</pub-id><pub-id pub-id-type="pmcid">PMC6783505</pub-id></mixed-citation></ref><ref id="alz13879-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="alz13879-cit-0054"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Schindler</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>G</given-names></string-name>, et al. <article-title>Investigating white matter neuroinflammation in Alzheimer disease using diffusion‐based neuroinflammation imaging</article-title>. <source>Neurology</source>. <year>2024</year>;<volume>102</volume>(<issue>4</issue>):<elocation-id>e208013</elocation-id>.<pub-id pub-id-type="pmid">38315956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000208013</pub-id><pub-id pub-id-type="pmcid">PMC10890836</pub-id></mixed-citation></ref><ref id="alz13879-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="alz13879-cit-0055"><string-name name-style="western"><surname>Duering</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Finsterwalder</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baykara</surname><given-names>E</given-names></string-name>, et al. <article-title>Free water determines diffusion alterations and clinical status in cerebral small vessel disease</article-title>. <source>Alzheimers Dement</source>. <year>2018</year>;<volume>14</volume>(<issue>6</issue>):<fpage>764</fpage>‐<lpage>774</lpage>.<pub-id pub-id-type="pmid">29406155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jalz.2017.12.007</pub-id><pub-id pub-id-type="pmcid">PMC5994358</pub-id></mixed-citation></ref><ref id="alz13879-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="alz13879-cit-0056"><string-name name-style="western"><surname>Signore</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>. <article-title>Leptin neuroprotection in the CNS: mechanisms and therapeutic potentials</article-title>. <source>J Neurochem</source>. <year>2008</year>;<volume>106</volume>(<issue>5</issue>):<fpage>1977</fpage>‐<lpage>1990</lpage>.<pub-id pub-id-type="pmid">18466320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1471-4159.2008.05457.x</pub-id><pub-id pub-id-type="pmcid">PMC2634657</pub-id></mixed-citation></ref><ref id="alz13879-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="alz13879-cit-0057"><string-name name-style="western"><surname>Folch</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pedrós</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Patraca</surname><given-names>I</given-names></string-name>, et al. <article-title>Neuroprotective and anti‐ageing role of leptin</article-title>. <source>J Mol Endocrinol</source>. <year>2012</year>;<volume>49</volume>(<issue>3</issue>):<fpage>R149</fpage>‐<lpage>156</lpage>.<pub-id pub-id-type="pmid">22967480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1530/JME-12-0151</pub-id></mixed-citation></ref><ref id="alz13879-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="alz13879-cit-0058"><string-name name-style="western"><surname>Figley</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Uddin</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kornelsen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Puig</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Figley</surname><given-names>TD</given-names></string-name>. <article-title>Potential pitfalls of using fractional anisotropy, axial diffusivity, and radial diffusivity as biomarkers of cerebral white matter microstructure</article-title>. <source>Front Neurosci</source>. <year>2021</year>;<volume>15</volume>:<elocation-id>799576</elocation-id>.<pub-id pub-id-type="pmid">35095400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnins.2021.799576</pub-id><pub-id pub-id-type="pmcid">PMC8795606</pub-id></mixed-citation></ref><ref id="alz13879-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="alz13879-cit-0059"><string-name name-style="western"><surname>Lee</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>Y</given-names></string-name>. <article-title>Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers</article-title>. <source>Exp Mol Med</source>. <year>2019</year>;<volume>51</volume>(<issue>5</issue>):<fpage>1</fpage>‐<lpage>10</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s12276-019-0250-2</pub-id><pub-id pub-id-type="pmcid">PMC6509326</pub-id><pub-id pub-id-type="pmid">31073121</pub-id></mixed-citation></ref><ref id="alz13879-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="alz13879-cit-0060"><string-name name-style="western"><surname>Cullen</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Leuzy</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Janelidze</surname><given-names>S</given-names></string-name>, et al. <article-title>Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<fpage>3555</fpage>.<pub-id pub-id-type="pmid">34117234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-23746-0</pub-id><pub-id pub-id-type="pmcid">PMC8196018</pub-id></mixed-citation></ref><ref id="alz13879-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="alz13879-cit-0061"><string-name name-style="western"><surname>Chételat</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Arbizu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barthel</surname><given-names>H</given-names></string-name>, et al. <article-title>Amyloid‐PET and (18)F‐FDG‐PET in the diagnostic investigation of Alzheimer's disease and other dementias</article-title>. <source>Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>(<issue>11</issue>):<fpage>951</fpage>‐<lpage>962</lpage>.<pub-id pub-id-type="pmid">33098804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30314-8</pub-id></mixed-citation></ref><ref id="alz13879-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="alz13879-cit-0062"><string-name name-style="western"><surname>Cipollini</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Troili</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Giubilei</surname><given-names>F</given-names></string-name>. <article-title>Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application</article-title>. <source>Int J Mol Sci</source>. <year>2019</year>;<volume>20</volume>(<issue>11</issue>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20112812</pub-id><pub-id pub-id-type="pmcid">PMC6600494</pub-id><pub-id pub-id-type="pmid">31181792</pub-id></mixed-citation></ref><ref id="alz13879-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="alz13879-cit-0063"><string-name name-style="western"><surname>Gold</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Johnson</surname><given-names>NF</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>CD</given-names></string-name>. <article-title>White matter integrity and vulnerability to Alzheimer's disease: preliminary findings and future directions</article-title>. <source>Biochim Biophys Acta</source>. <year>2012</year>;<volume>1822</volume>(<issue>3</issue>):<fpage>416</fpage>‐<lpage>422</lpage>.<pub-id pub-id-type="pmid">21803153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2011.07.009</pub-id><pub-id pub-id-type="pmcid">PMC3213315</pub-id></mixed-citation></ref><ref id="alz13879-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="alz13879-cit-0064"><string-name name-style="western"><surname>Araque Caballero</surname><given-names>MÁ</given-names></string-name>, <string-name name-style="western"><surname>Suárez‐Calvet</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Duering</surname><given-names>M</given-names></string-name>, et al. <article-title>White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease</article-title>. <source>Brain</source>. <year>2018</year>;<volume>141</volume>(<issue>10</issue>):<fpage>3065</fpage>‐<lpage>3080</lpage>.<pub-id pub-id-type="pmid">30239611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awy229</pub-id><pub-id pub-id-type="pmcid">PMC6158739</pub-id></mixed-citation></ref><ref id="alz13879-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="alz13879-cit-0065"><string-name name-style="western"><surname>Shafer</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>OA</given-names></string-name>, <string-name name-style="western"><surname>Perez</surname><given-names>E</given-names></string-name>, et al. <article-title>Accelerated decline in white matter microstructure in subsequently impaired older adults and its relationship with cognitive decline</article-title>. <source>Brain Commun</source>. <year>2022</year>;<volume>4</volume>(<issue>2</issue>):<elocation-id>fcac051</elocation-id>.<pub-id pub-id-type="pmid">35356033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/braincomms/fcac051</pub-id><pub-id pub-id-type="pmcid">PMC8963308</pub-id></mixed-citation></ref><ref id="alz13879-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="alz13879-cit-0066"><string-name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, et al. <article-title>The associations between white matter disruptions and cognitive decline at the early stage of subcortical vascular cognitive impairment: a case–control study</article-title>. <source>Front Aging Neurosci</source>. <year>2021</year>;<volume>13</volume>:<elocation-id>681208</elocation-id>.<pub-id pub-id-type="pmid">34408641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2021.681208</pub-id><pub-id pub-id-type="pmcid">PMC8364958</pub-id></mixed-citation></ref><ref id="alz13879-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="alz13879-cit-0067"><string-name name-style="western"><surname>Califf</surname><given-names>RM</given-names></string-name>. <article-title>Biomarker definitions and their applications</article-title>. <source>Exp Biol Med</source>. <year>2018</year>;<volume>243</volume>(<issue>3</issue>):<fpage>213</fpage>‐<lpage>221</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1535370217750088</pub-id><pub-id pub-id-type="pmcid">PMC5813875</pub-id><pub-id pub-id-type="pmid">29405771</pub-id></mixed-citation></ref></ref-list></back></article>